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Lauren R. Bringman 
SPECIFICITY PROTEIN 1 INDUCES THE EXPRESSION OF ANGIOMOTIN IN 
RESPONSE TO IL-6/STAT3 ACTIVATION TO MEDIATE YAP-DEPENDENT 
GROWTH OF BREAST CANCER CELLS 
 
Chronic inflammation is a major driver of tumor progression in over fifty 
percent of breast cancers. Tumors activate inflammatory processes by secreting 
factors that recruit and trigger inflammatory cells to release cytokines such as 
Interleukin 6 (IL-6). IL-6 stimulates the activity of signal transducers and 
activators of transcription 3 (STAT3), a transcription factor that has been 
extensively studied for its role in promoting breast cancer. Recently, 
downregulated HIPPO signaling was shown to drive the pro-growth effects of IL-
6. Reduced HIPPO signaling allows for the nuclear translocation of 
transcriptional co-activator yes associated protein (YAP), implicating IL-6 in the 
co-activation of several transcription factors such as the TEADs that trigger pro-
growth programs. While IL-6/STAT3 stimulation has been shown to increase 
YAP activity, the mechanism driving this remains undocumented. The 
Angiomotins (Amots) are adapters of the HIPPO pathway that directly bind and 
regulate YAP activity. Molecular characterization of Amot transcriptional 
regulation unexpectedly revealed a single promoter controlling the expression of 
its two major isoforms: Amot 130 and Amot 80. Through immunofluorescent 
analysis, this study found that total Amot levels were elevated across multiple 
breast tumor subtypes and highest in samples with increased presence of 
stromal inflammatory cells.  Further, the induction of total Amot expression by IL-
6 was found to be essential for YAP dependent growth of breast cancer cells. 
  
viii 
The activation of Amot transcription by IL-6 was found to be through Specificity 
Protein 1 (Sp1), a transcription factor that is activated by STAT3. This work 
connects the activation of YAP1 by IL-6/STAT3 through the elevation of Amot 
expression by Sp1. Taken together, this explains a new avenue whereby breast 
cancer cells acquire enhanced oncogenic properties in response to inflammatory 
signaling. 
 
               Clark D. Wells, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
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1.1 Current facts regarding breast cancer incidence and treatments in the United 
States. 
Despite many advances, breast cancers continue to claim the lives of 
approximately 1 in every 12,000 women in the United States each year, and 
global incidence of the disease has increased thirty-percent over the past decade 
[1]. The transition from the pre-invasive state of ductal carcinoma in situ (DCIS) 
to the more aggressive state of invasive ductal carcinoma (IDC) is a major area 
under investigation [2].  
DCIS describes a pre-neoplastic state in which an intra-ductal population 
of heterogeneous hyperplastic cells aberrantly accumulate, yet remain contained 
within a polarized mammary duct [3,4]. IDC tumors have already spread locally 
within the surrounding breast tissue [5]. Nationwide mammogram screening data 
demonstrate that nearly 25 % of breast abnormalities result in the diagnosis of 
DCIS. Although DCIS is not an obligate precursor to IDC, DCIS to IDC transitions 
occur in approximately 50 % of women who do not seek immediate treatment 
after a DCIS diagnosis [5-8].  There is no known cause or predictor of DCIS to 
IDC transitions; the current standard for treatment of all DCIS cases is surgical 
excision followed by radiation and/or chemotherapy [6]. This conservative 
treatment is predominantly to prevent the development of the very aggressive 
inflammatory breast cancer (IBC) phenotype; DCIS precurses these highly fatal 
diagnoses in 15-20 % of cases. However, surgical excision is also successful in 
the prevention of transition to IDC [7]. Taken together, these nationwide statistics 
tell us that 50 % of DCIS cases will transition to IDC, 15-20 % will transition to 
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IBC, and 30-35 % will not experience any cancer progression [7]. This means 
that of the 60,290 new diagnosis of DCIS in 2015, 18,087 surgeries removed 
lesions that would likely not progress to either IDC or IBC [8]. The Oncotype DX 
DCIS Score ©, a twelve gene expression assay, has demonstrated proficiency in 
predicting local recurrence of node-negative breast cancer already treated with 
both surgical excision and tamoxifen [9]. Similarly, MammaPrint ©, a seventy 
gene expression assay for surgically excised breast tumor tissue, successfully 
predicts the potential efficacy of chemotherapy treatment [10]. Although clinical 
investigations of breast cancers have greatly advanced the field by incorporating 
mammary tumor histologic analysis and biomarker composition as tools to 
enhance diagnosis and prognosis, there is still no method to distinguish between 
the patients that stand to benefit from tumor resection and those that do not need 
surgery [11].  
While the diagnosis of DCIS indicates a three-fold increase in the 
likelihood for the development of IDC, the integrity of both the ductal epithelial 
and myoepithelial layers can act to prevent intra-ductal hyperplasia from 
transitioning to IDC by invading the surrounding stroma [11,12]. The field 
currently lacks a comprehensive understanding of the signaling pathways that, 
when dysregulated, contribute to the degradation of polarized ductal epithelial 
tissue. The absence of this knowledge hinders the improvement of current 
prognoses and treatments, and leaves key questions regarding the natural 
history of this disease unanswered [13,14]. The work described in this 
dissertation seeks to provide a greater appreciation for the dysregulation of 
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pathways that support a polarized ductal epithelium, a potential cause of the 
transition of pre-invasive ductal carcinoma in situ (DCIS) to the aggressive state 
of invasive ductal carcinoma (IDC) [4,15].  
 
1.2 The overview of mammary tissue polarity and its de-regulation in breast 
cancer. 
The study of the natural history of the breast begins with the 
understanding the structure of normal breast physiology. The cross-sectional 
structure of the functional mammary gland is comprised of a myoepithelial outer 
layer adjacent to a stratum of polarized epithelium that surround a hollow inner 
lumen. Longitudinally, this structure forms a long hollow hose that extends 
toward the nipple. The duct is nestled within layers of adipose tissue capable of 
synthesizing and secreting various hormones [16]. Upon the activation via 
hormonal signaling, the mammary gland is designed to secrete and deliver 
breast milk to a suckling infant (Fig. 1-1, 1-2 (Left)). The health and function of 
the mammary duct requires the maintenance of a strongly polarized epithelium 
[17,18]. Paradoxically, this requires a regular regeneration cycle that involves the 
depolarization, cellular clearing, regrowth, and re-polarization of new epithelial 
cells. Additionally, this standard regeneration cycle is accompanied by several 
more drastic remodeling events that comprise the natural history of the breast, 
including pubertal expansion, pregnancy/lactation-associated remodeling, and 
post-lactational/menopausal associated involution (Fig. 1-3) [13]. At the cellular 
level, these major remodeling events require the modulation of epithelial  
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Figure 1-1. A schematic of the structure of a normal breast and 
mammary gland. The normal human female breast is comprised of polarized 
mammary epithelial tissue surrounded by a layer of myoepithelial and stromal 
cells. Longitudinally, the mammary duct forms an extended tubular structure: 
The lobules and terminal ducts point toward the breast bone and extend all the 
way to the nipple. The myoepithelial cells add integrity and flexibility to the 
tubule, allowing for gentle squeezing in the event of milk secretion. 
Latitudinally, the mammary duct is composed of polarized epithelial cells with 
strong cell-cell contacts that support a permeable barrier separating the 
intraductal lumen from the stroma. These structures are supported by 
hormone producing adipose tissue. Figure designed by Clark Wells, PhD. and 
adapted by Lauren Bringman May 2016. 
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Figure 1-2. Comparison of a normal mammary duct and tumorigenic 
mammary duct exhibiting DCIS. This haemotoxylin and eosin (H&E) staining of 
normal mammary tissue displays a hollow lumen and healthy stroma, and DCIS 
mammary tissue displays a lumen positive for tumor cells and stroma with 
lymphocytic infiltration. Nuclei are stained purple and stromal and connective 
tissue are stained in pink. Slides were provided by George Sandusky, PhD. and 
were stained and imaged by Lauren Bringman.  
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Figure 1-3. The organogenesis of the mammary gland. Images of murine 
mammary tissue whole mount slides representing all of the phases of 
glandular development. Image 1 represents the pre-pubertal mammary tissue 
of a 2-week old pup and displays minimal presence and branching of ductal 
structures. Image 2 represents the pubertal mammary tissue of a 5-week old 
mouse, and displays a significantly enhanced presence and increased 
branching of ductal structures. Image 3 represents the adult mammary tissue 
of a 10-week old mouse and displays highly organized and branched ductal 
structures. Image 4 represents the mammary tissue during gestation of a 
pregnant mouse (gestation day 18.5) and displays a significant increase in the 
number and size of ducts. Image 5 represents the mammary tissue during 
lactation and displays enlarged ductal structures likely engorged with milk. 
Image 6 represents the involuting mammary gland of a mouse 8 days post-
lactation and displays the a return of the number and size of ductal structures 
to that of the pre-gestational adult mouse. The cycle of morphological changes 
between the adult, gestational, lactating, and involuting mammary tissue is 
known as the pregnancy and lactation cycle (PLC). These images collectively 
represent the highly dynamic structure of the mammary gland. Scale bars = 1 
mm. Figure designed by William Ranahan. Figure adapted from [1]. 
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cell polarity.  A polarized epithelial layer can contain hundreds of apico-basal 
epithelial cells held tightly together via tight and adherens junctions. This 
structure is represented in a wide variety of body tissues including the inner lining 
of the gastrointestinal tract and uterus, and the outer layers of the epidermis [19]. 
These tightly bound cells support the health of ductal tissue by functioning as a 
permeable barrier that carefully filters the exchange of molecules, cells, and 
other tissue debris between cells from the basal face to the apical face, and vice 
versa (Fig. 1-4). This organization underlies proper milk secretion by the 
mammary gland [20-22].  
Changes to the exterior cell structure modify internal cell signaling. The 
subcellular localization of proteins that mediate signaling that translates external 
cues onto cellular behavior differs dramatically between an actively proliferating 
cell and a polarized cell [23-25]. Highly polarized ductal epithelial cells are growth 
arrested due to active growth controlling signaling pathways such as the HIPPO 
signaling pathway [26,27]. In contrast, the loss of cell polarity enables growth by 
inactivating HIPPO signaling and the wiring of growth promoting pathways such 
as the mitogen activated protein kinase (MAPK) signaling pathway [12,28,29]. 
The primary cues supporting cell polarity include the formation of tight junctions 
and adherence junctions. Their formation dictates cell shape, which in turn drives 
the asymmetrical organization of organelles, the cytoskeleton, and most protein 
complexes [24,30] (Fig 1-4). 
The dysregulation of mechanisms that control cellular polarity is intricately 
connected to the development and progression of cancer. The cyclical  
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Figure 1-4. The structure of two contacted epithelial cells. Polarized 
epithelial cells possess three distinct faces (i.e. lateral, basal, and apical) that 
are maintained by the contact through junctional protein complexes adherence 
and/or tight junctions. The structural polarity signals intracellular polarity with 
respect to protein localization and cytoskeletal structure. Permeability is 
restricted which prevents molecules from transferring through the epithelial 
stratum. Figure was designed by Clark Wells, PhD. and adapted by Lauren 
Bringman. 
Nucleus Nucleus
CytosolCytosol
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neoplastic outcomes [17]. For instance, if cells remain depolarized, the proteins 
that drive transcriptional programs that promote cellular divisions are often no 
longer sequestered from the nucleus and thereby can induce aberrant cell 
divisions associated with hyperplastic growth in the mammary duct. If this cell 
happens to contain a pro-oncogenic mutation, then the ability of that 
constitutively active protein to transmit signaling is greatly amplified [31] [32]. 
One of the best examples of this occurring is in the ability of chronic inflammation 
to promote carcinogenesis in epithelial tissue composed of cells that contain 
oncogenic mutations.  Through the release of pro-growth factors such as 
cytokines, inflammation activates the sustained dedifferentiation and proliferation 
of otherwise highly polarized, growth arrested cells.   
 
1.3 Inflammation and Cancer 
The connection between the immune system and cancer is 
overwhelmingly two-sided. One on hand, over eleven new classes of 
immunotherapeutic drugs aimed at stimulating the antitumor immune response 
have been developed in the last 10 years [33].  Yet, on the other hand, the 
impacts of chronic inflammation on tumorigenesis have also been widely 
observed for centuries [34-37]. For example, thorough investigation into this link 
by thousands of groups has demonstrated that an inflammatory 
microenvironment is unequivocally critical for the support of tumor growth and 
progression in a variety of tissue types [38]. Martel and Franceschi 2009 were 
first to establish and categorize the correlation between bacterial and/or viral 
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infection induced inflammation and the increased risk of cancer development 
[39,40]. Additionally, accumulating evidence indicates that the carcinogenicity of 
tobacco products is due in large part to their ability to establish a chronic 
inflammatory state in the lung tissue [41]. More surprisingly, chronic inflammation 
has been shown to correlate with a marked reduction in chemotherapeutic 
efficacy [42]. Accumulation of damaged DNA and cell senescence within a cell 
can produce secreted protein-based pathogens that initiate an immune response. 
[43,44]. 
 
1.4 Wound healing as a model to understand the impact of inflammation in 
epithelial systems. 
The connection between inflammation and cancer was first observed by 
Rudolf Virchow in 1863 who noted the high frequency in which tumors develop in 
post-trauma fibrotic tissue [34]. The mechanisms underlying wound healing are 
key in the study of epithelial cell depolarization in response to inflammatory cues 
(Fig 1-5). Wound healing is defined as the remodeling of tissue damaged through 
physical or chemical trauma.  This occurs through a tightly regulated program 
involving the dedifferentiation, proliferation, migration, and redifferentiation of the 
cells composed in and around the wound site. Wound healing is characterized by 
three phases of tissue remodeling: inflammatory, fibroblastic, and re-
epithelialization (Fig 1-5). These three events have been shown to take place in 
the pro-inflammatory tumor microenvironment (Fig. 1-6) [45,46].  
 
  
12 
 
 
 
 
Figure 1-5. The morphology of a healing skin wound. The inflammatory 
phase of wound healing initiates a rapid influx of macrophages and 
neutrophils, followed by the recruitment of lymphocytes that drive the 
production of pro-inflammatory cytokines that protect host epithelial cells from 
the toxic environment created by the complement cascade of proteolysis. Pro-
inflammatory cytokines such as IL-6 signal the epithelial cells to survive, 
proliferate, and induce the profibrotic phase through the production of pro-
fibrotic growth factors such as CTGF to drive the development of new 
connective tissue. In the re-epithelialization phase, the production of laminin 
and other pro-differentiation factors fosters enhanced cell polarity to drive the 
re-epithelialization of the tissue cells and facilitate wound closure.  
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Figure 1-6. The comparison of the wound healing phenotype to the 
cancer phenotype. An illustration of an invasive tumor (a) as it compares to 
a healing wound (b). Both phenotypes are characterized by the influx of 
inflammatory cells, fibrosis, and vascularization. 
 
 
 
 
 
 
\ 
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1.4.1 Wound Healing: The Inflammatory Phase 
Inflammation is a defensive response from the connective tissue 
surrounding a wound site which functions to abolish the source of damage, 
eliminate pathogenic invasion, and repair damaged tissue cells [45]. The 
inflammatory phase commences upon tissue damage by activating a localized 
acute inflammatory response that involves a vascular reaction followed by a cell 
based reaction [45,47].  Blood vessels surrounding the damage site enlarge to 
increase blood and nutrient supply, and pro-proteins found in the blood undergo 
cleavage and subsequent activation by what is known as the complement 
protease cascade. This cleavage of over thirty complement-associated proteins 
creates a toxic microenvironment that facilitates the opsonization of bacterial and 
viral invaders by neutrophils, lysis of foreign cells, and agglutination of pathogens 
for degradation. These processes also induce the recruitment of macrophages 
and lymphocytes by chemotaxis, which initiates the cell-based inflammatory 
reaction [48-50].  Macrophages engulf cellular debris to neutralize the otherwise 
toxic environment. T-lymphocytes secrete cytokines and also activate 
macrophages to follow suit. These cytokines are small proteins (5-20 kDa) that 
bind and signal host epithelial cells to initiate host protective responses including 
apoptotic evasion, dedifferentiation, and proliferation in spite of the toxic 
inflammation microenvironment [45,51,52]. The inflammatory phase of wound 
repair induces the eradication of foreign invaders and promotes the regrowth of 
healthy cells to comprise the newly repaired tissue. While the infiltration of 
inflammatory cells is a hallmark of cancer, the roles of the inflammatory phase of 
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wound repair in cancer development is a very active area of ongoing research 
[36,37].   
1.4.2 Wound Healing: The Fibroblastic Phase 
The fibroblastic phase of wound repair initiates fibrosis, a process in which 
the supportive connective tissue is rebuilt. Connective tissue underlies mammary 
epithelium, originates from mesenchyme, and is comprised of fibroblasts, 
macrophages, mast cells, neutrophils and lymphocytes [53,54]. Fibrosis rebuilds 
the structural and chemical foundation to support the integrity and health of the 
newly repaired tissue. Structurally, this often results in the development of visible 
and occasionally palpable scar tissue [55]. The connective tissue supporting 
mammary epithelium possesses both a loose and dense consistency, and is 
classified as irregular, in which thick, multi-planar fibers make up fibrous 
capsules that surround the gland.  This is in contrast to regular connective tissue 
including tendons, ligaments, cartilage, and blood, which all contain thin single 
planar fibers [56].  
The fibrotic process is initiated by pro-fibrotic growth factors that are 
secreted by proliferating epithelial cells at the wound site in response to their 
exposure to pro-inflammatory cytokines such as interleukin (IL-6). Of these pro-
fibrotic factors, Connective Tissue Growth Factor (CTGF) is one of the most 
studied and most important factors in this process [57-59]. In physiological 
wound healing, CTGF directs fibrosis signaling that underlies scar formation 
through its ability to induce cells to secrete extra-cellular matrix components. The 
resulting accumulation of ECM facilitates vascularization and immune cell 
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recruitment at the site of the wound. Increased levels of CTGF in sera, urine, and 
plasma is a clinically dominant diagnostic marker for fibrosis [60,61]. 
Pathologic/inappropriate CTGF signaling fosters a tumor promoting environment 
[62-66]. 
 
1.4.3 Wound Healing: The Re-Epithelialization Phase 
The reformation of connective tissue in the fibroblastic phase of wound 
healing provides the foundation that fosters the seeding of new cells for re-
epithelialization (differentiation). Re-epithelialization is necessary for complete 
wound closure, where a tight permeable barrier from the re-establishment of cell 
to cell junctional complexes is formed [67-69]. In skin wounds, re-epithelializing 
keratinocytes exhibit a lamellipodial cell structure, characteristic of mesenchymal 
migration [68]. This indicates the dynamic role that newly proliferated cells play; 
their migration is both calculated and highly organized.  
Once new cells arrange in the correct organization, they begin to 
differentiate into polarized epithelial cells where cell-cell contact initiates signaling 
that induces expression and junctional localization of tight and adherens complex 
proteins. In addition, these sub-basal layer cells are signaled to organize their 
basement membranes in response to contact with the laminin freshly remodeled 
connective tissue [68-69].   
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1.4.4 From wound healing to cancer: EMT with no MET 
The wound healing cycle requires several dramatic changes in cell 
structure. This initiates when polarized epithelial cells are induced to de-
differentiate into primitive mesenchymal cells, an event appropriately named an 
epithelial to mesenchymal transition (EMT) [23,70]. During an EMT event, cells 
lose cell-cell contacts to allow for their reorganization which is significantly 
mediated by the induction of new pro-EMT transcriptional programs that result in 
decreased expression of E-Cadherin and increased expression of N-Cadherin, 
Vimentin, Snail, and Twist. Re-epithelialization in physiological wound healing 
drives the reversed transition of cells from a mesenchymal phenotype to the 
more differentiated epithelial phenotype, known as an MET event. These newly 
differentiated epithelial cells regain E-Cadherin expression and again lose N-
Cadherin, Vimentin, Snail, and Twist expression (Fig 1-7) [71]. In addition to 
wound healing, normal physiology requires the process of EMT / MET under 
instances of healthy tissue remodeling, such as in the maintenance of the 
mammary gland [16,72,73]. 
The field of breast cancer research has focused a great deal of attention 
on the concept of EMTs as a necessity for the initiation and promotion of breast 
cancers. Pathological EMTs occur in response to inappropriate signaling from the 
extracellular matrix, and direct the loss of a polarized epithelial layer. This 
process is highly exploited in various carcinomas to effect the initiation of cellular 
invasion programs associated with metastasis. In the mammary duct, EMTs 
create a “leaky duct” that can no longer prevent oncogenic cells that fill the intra- 
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they are free to invade the surrounding stroma and to eventually metastasize by 
entering the  
EMT 
MET 
A polarized epithelial cell 
is marked by: 
Cell-to-Cell Junctions 
High E-Cadherin 
Expression 
Low V-Cadherin, 
Vimentin, Snail, and Twist 
Expression 
A primitive mesenchymal 
cell is marked by: 
No Cell-to-Cell Junctions 
Low E-Cadherin  
Expression 
High V-Cadherin, 
Vimentin, Snail, and Twist 
Expression 
Figure 1-7. Diagram of an epithelial-to-mesenchymal transition (EMT/ 
mesenchymal-to-epithelial transition (MET). Polarized epithelial cells lose cell-
to-cell contacts and levels of E-cadherin, and gain an increase in V-cadherin, 
vimentin, snail, and twist levels (EMT) and vice versa (MET). EMT events occur 
during the regular remodeling of epithelial tissue, as well as in tumorigenesis.  
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ductal lumen from invading into the surrounding stroma [23,70,72-77]. Thus, the 
initiation of EMTs is a major process contributing to the transition of DCIS to IDC 
[78]. Further, once the cells break free from adjacent cells in the mammary duct, 
they are free to invade the surrounding stroma and to eventually metastasize by 
entering the bloodstream which allows their dissemination to distant secondary 
sites. This concept comprises the dogma that the maintenance of epithelial 
polarity is a fundamental tumor suppressive mechanism at both the cellular and 
tissue levels [17,18,79]. 
 
1.5 Mammary cell depolarization in response to Interleukin 6 signaling 
The secretion of interleukin 6 (IL-6) by macrophages and lymphocytes has 
been directly linked to driving pathological EMT events in the breast [70,72,75-
77]. First discovered by Hirano et al.1986, IL-6 is a 27 kDa soluble cytokine that 
is commonly upregulated in the immune cells that respond to wound healing, 
sites of infection, and tumorigenesis [80]. Throughout the progression from 
normal breast tissue to infiltrative ductal carcinoma (IDC), increased infiltration of 
inflammatory cells that secrete cytokines into the parenchymal and stromal tissue 
ensues. The presence of CD3+ T cells, CD68+ macrophages, and CD+20 cells is 
elevated, with the presence of highly secreting activated T cells increasing most 
prevalently [3]. T-lymphocytes and macrophages, when activated, upregulate 
and secrete IL-6 [35,80]. IL-6 has been found to signal host cells to initiate a 
variety of cell programming events to direct survival, proliferation, angiogenesis, 
etc. Inappropriate signaling by IL-6 plays a dramatic role in tumorigenesis and 
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tumor progression. Serum levels of Interleukin 6 (IL-6) are elevated in the stroma 
surrounding the tumorigenic mammary gland.  
IL-6 promotes pro-tumorigenic effects by binding to cell surface receptors 
linked to the Janus Kinase (JAK)-coupled receptors subcellular localization 
that in turn phosphorylate and activate members of the signal transducers and 
activators of transcription (STAT) family, in particular STAT1 and STAT3 [3,81-
83]. Of the seven STAT proteins, STAT3 is most commonly identified in a 
constitutively phosphorylated form in cancers. Phosphorylated STAT3 (P-STAT3) 
has been extensively studied for its role in activating the transcription of specific 
genes that promote cancer [72,84,85]. Specifically, STAT3 signaling occurs when 
extracellular IL-6 binds to the IL-6 receptor (IL-6R) present on the surface of 
epithelial cells. The IL-6R contains two subunits, gp130 and gp80. Once the 
conformational change is induced via IL-6 ligand binding, the activation of the 
Janus Kinases 1/2 (JAK 1/2) proceeds via gp130. JAK1/2 function to 
phosphorylate STAT3. The phosphorylation event of STAT3 exposes an SH2 
domain, which provides a high affinity binding site for a homodimer to form. This 
rapid homodimerization event correlates so highly with the phosphorylated state 
of STAT3 that P-STAT3 is assumed to always exist in a homodimer complex. 
STAT3 homodimerization reveals a powerful set of nuclear localization 
sequences, which drive the nuclear translocation of P-STAT3 and promotes the 
activation of thousands of pro-growth and pro-survival genes [81,86].   
It has been estimated that more than three thousand promoters are bound 
and directly activated by P-STAT3 [87]. Additionally, through the upregulated 
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expression of many transcription factors by STAT3, the number of promoters that 
are indirectly activated by STAT3 is nearly immeasurable.  For instance, STAT3 
activates the transcriptional expression of the transcription factor Specificity 
Protein 1 (SP1), which, in turn, also activates the transcription of over 3000 
promoters [87]. SP1 is an 81 kDa protein and one of the nine proteins belonging 
to the Specificity Protein/Kruppel-Like Factor (Sp/KLF) family of zinc finger 
transcription factors. These transcription factors specifically bind to GC boxes 
contained in thousands of gene regulatory regions. Sp1, in particular, has been 
shown to directly activate the transcription of genes that regulate chromatin 
remodeling and DNA damage repair, cell growth, differentiation, apoptosis, and 
even immune responses [74,88-92]. The increased expression of Sp1 by P-
STAT3 is implicated in the uncontrolled growth of cancer cells [87,88,93].  
P-STAT3 has also been reported to regulate biochemical signaling 
mechanisms independent of its DNA binding function. For example, P-STAT3 
has been implicated in the nuclear recruitment of other transcription factors. 
Interestingly, an example of this lies in the crosstalk between STAT3 and Sp1 
[87].  Sp1 and STAT3 have been shown to co-dependently activate the 
transcription of a variety of genes with promoters that contain adjacent Sp1 and 
STAT3 binding sites including JAK3 and C/EBPdelta [93-95]. Additional studies 
have found that the physical interaction of STAT3 and Sp1 is induced by IL-6 to 
facilitate the promoter activation of the calcium-sensing receptor (CASR) gene 
[93]. 
P-STAT3 and SP1 have both been shown to bind the promoter of pro-
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fibrotic factor CTGF [96]. In addition to driving fibrosis and ECM accumulation, 
CTGF also triggers proliferation, mitogenesis, apoptotic evasion, chemotaxis 
(directional cell migration), chemokinesis (random migration), invasion, and 
inflammatory cell infiltration, and has been implicated in the driving of EMTs [57-
59,64,97-101]. CTGF is upregulated in response to IL-6 [57]  and has also shown 
to be activated by Sp1 to promote dedifferentiation via signaling through 
Transforming Growth Factor β (TGFβ) [74]. Elevated CTGF levels are found in 
melanoma, pancreatic cancer, breast cancer, and in the regenerating liver, and is 
implicated in cardiac immunorejection and fibrotic disease of the kidney and liver 
[52,57,58,62,65,66,102]. CTGF possesses far more TEA Domain (TEAD) binding 
sites in its promoter than STAT3 and Sp1 binding sites  [96], and its promoter 
activation is dramatically enhanced by occupancy by the yes-associated protein 
(YAP1)-TEAD nuclear complex [103-105]. The predominant pathway which 
antagonizes YAP1-TEAD dependent activation of pro-tumorigenic CTGF 
signaling and maintains epithelial polarity is the HIPPO Signaling Pathway 
[19,106,107]. 
 
1.6 HIPPO signaling promotes epithelial cell polarity 
Recently, the HIPPO signaling pathway, as a promoter of intracellular 
epithelial polarity, has been demonstrated to resist EMT events [108]. The 
HIPPO signaling pathway was first discovered in Drosophila melanogaster 
through the execution and analysis of mosaic screenings for mutant tumor 
suppressor proteins [109]. The ablation of a number of HIPPO pathway 
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components yielded dramatic cell overgrowth and apoptotic evasive phenotypes, 
implying a widespread tumor suppressive characteristic of the HIPPO signaling 
pathway [109-111]. Further studies revealed the pathway’s high activity in 
development through the control of organ size [112]. Since its elucidation in 
Drosophila just over 20 years ago, the study of HIPPO signaling has been 
appreciated to function in all metazoans including humans in almost 1100 
completed studies. 
HIPPO Pathway Signaling can be broken down into two main 
components. 1. The growth inhibitory serine/threonine kinase component and 2. 
The growth activating transcriptional component. The kinases in the first 
component include mammalian STE20-like protein kinase 1 and 2 (MST1/2) and 
large tumor suppressor 1 and 2 (LATS 1/2) and function to terminate growth 
when active. The transcriptional coactivators in the second HIPPO pathway 
component include functional analogues yes associated protein (YAP1) and 
transcriptional coactivator with a PDZ binding motif (TAZ) [109,111,113]. The 
kinases in component 1 function to phosphorylate and thereby inactivate the 
coactivators in component 2. This phosphorylation event inhibits YAP1 and TAZ 
by allowing their association with protein 14-3-3 and enable their sequestration in 
the cytosol. In cases where MST1/2 and LATS1/2 remain inactive, 
unphosphorylated YAP1 and TAZ are free to translocate to the nucleus where 
they stimulate the transcription of pro-growth and –survival genes. Both YAP1 
and TAZ stimulate growth and cell survival when active (Fig. 1-8; 1-9) 
[112,114,115].  
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Figure 1-8. Regulation of intracellular cell polarity is innervated by the 
HIPPO Signaling Pathway. Tight and/or adherens junctions aid in the control 
of cell shape and the intracellular protein localization. In response to external 
cues of polarization, such as cell-to-cell contact through adherens and tight 
junctions, the HIPPO Signaling Pathway directs intracellular polarity upon the 
activation of HIPPO pathway kinase cascade involving mammalian STE20-like 
protein kinase 1 and 2 (MST 1/2) and large tumor suppressor 1 and 2 
(LATS1/2) which, in turn, phosphorylate HIPPO co-activators YAP1 and TAZ. 
These phosphorylation events encourage either their degradation or their 
binding and cytosolic sequestion by the tumor suppressor 14-3-3. These 
cytosolic events prevent the nuclear translocation of YAP1 and TAZ, thus 
preventing the coactivation of transcription factors that stimulate the 
transcription of multiple pro-growth and pro–survival genes such as CTGF, 
Cyr61, Amphiregulin (AREG), BIRC6, and AmotL2.  
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Figure 1-9. The Functional Regions of the Transcriptional Co-activators YAP1 and 
TAZ. Both YAP1 and TAZ possess an N-terminal TEA domain (TEAD) 
transcription factor binding domain, a transactivation domain, serine 
phosphorylation sites, and a C-terminal PDZ binding motif. YAP1 possesses two 
WW (tryptophan-tryptophan) domains and TAZ possesses one. The TEAD 
domains allow for YAP1 and TAZ to bind and co-activate TEAD transcription 
factors 1, 2, 3, and 4. The trans-activation domains of YAP1 and TAZ have been 
shown to be required for their transcriptional coactivation activity. The serine 
phosphorylation sites allow for these proteins to be regulated via phosphorylation 
by LATS. The PDZ binding motifs allow for YAP1 and TAZ to interact with other 
proteins that possess PDZ binding motifs. Finally, the WW domains allow for 
YAP1 and TAZ to associate with various Angiomotin proteins and LATS which 
regulate their activity. 
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Through gene amplification and inactivation of HIPPO signaling, the direct 
enhancement of both YAP1 and TAZ levels correlates with enhanced malignancy  
in most cancers. Further, the activation of the tumor microenvironment that 
favors a loss of cell-cell contacts leads to neoplastic cell growth [103,104,116-
118]. Surprisingly, with the exception of a rarely occurring LATS2 mutant found in 
multiple myeloma, no germline or somatic mutations of any of the Hippo pathway 
components consistently occur in cancers. This led researchers to appreciate 
that the predominant mechanism including increased mechanotransduction or by 
mitogenic signaling through GPCRs. Taken together, it is clear that the 
dysregulation of the HIPPO pathway contributes greatly to tumorigenesis. 
 
1.7 YAP1 and TAZ as oncogenes 
Hyperactivation of YAP1 and TAZ is pervasive across a multitude of 
cancers, and has demonstrated sufficiency both in developing and sustaining 
tumor growth [21,30,104,110,116,119]. A variety of studies have shown that the 
inactivation of YAP1/TAZ regresses tumorigenic properties, including stemness, 
resistance to anoikis, migration, and metastatic potential. Nuclear YAP1/TAZ is 
also enhanced by highly stiff extra cellular matrices (ECMs), a common 
component in the tumor microenvironment due to elevated profibrotic and 
integrin signaling [120]. This is consistent with the recent link with YAP1 activity 
to the induction of an EMT event [121]. The importance of oncogenic YAP1 in 
driving neoplasia in NF2 deficient neurofibromatosis was demonstrated by 
pharmacologic inhibition of YAP1 reverting the otherwise rampant tumor growth 
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in NF2 mutant mice [122]. Pancreatic and lung cancers with overactive KRAS 
oncogene expression have also been found to have increased YAP1 activity that 
not only worked cooperatively with KRAS to drive tumorigenesis but that could 
also allow tumors to escape when treated with anti-KRAS therapies. Multiple 
studies indicate that activation of YAP1 increases the malignancy of breast 
cancers.  This includes histologic and genomic studies that find that tumors have 
increased levels of YAP1 mRNA transcript, reduced ratios of phospho-YAP1 over 
total YAP1, and increased YAP1 in the nucleus in a manner that increased in 
direct correlation with tumor malignancy [123-125]. Taken together, these data 
validate the widespread impact of YAP1 activity on tumorigenesis. 
 
1.8. Amot 130 and Amot 80 co-coordinate YAP1 and TAZ subcellular localization 
The Angiomotin family of adapter proteins also play significant roles in cell 
growth control and polarity by integrating the activities of cell polarity proteins 
with HIPPO signaling [126]. Unlike most Hippo pathway components, Angiomotin 
proteins do not have obvious Drosophila orthologs [127]. The highly conserved 
Angiomotin family of proteins is comprised of three separate genes, Amot, Amot 
Like 1, and Amot Like 2 that encode proteins that share a basic architecture 
comprising the Amot coiled coil homology domain (ACCH) that separates an N-
terminal region that binds to YAP1,TAZ, and LATS1 from a C-terminal region that 
associates with apical polarity proteins [128].  The AMOT gene yields two unique 
splice isoforms that result in the translation of Amot p130 and Amot p80 proteins 
[129]. Because the Amot p80 isoform lacks the region N-terminal to the ACCH  
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Figure 1-10. A Schematic Diagram of the Angiomotin Family. The 
Angiomotin family of adapter proteins is derived from three genes: Angiomotin 
(AMOT), Angiomotin Like 1 (AMOTL1), and Angiomotin Like 2 (AMOTL2). These 
genes generate four proteins Amot p130, Amot p80, Amot L1, and Amot L2 that 
share multiple common domains. All four proteins contain an Amot coiled-coil 
homology (ACCH) domain and a PDZ binding motif. The ACCH domain allows 
for homodimerization as well as heterodimerization within the Amot family, which 
has been shown to impact their behavior. The C-terminal PDZ binding motif 
allows these proteins to associate with other proteins containing a PDZ binding 
motif. Amot130, AmotL1 and AmotL2 all share N-terminal P-Y motifs that 
associate with the WW domains of Yap and Taz.  
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domain, it does not associate with YAP1 or TAZ (Fig. 1-10). In collaboration with 
Dr. Cristina Ivan (MD Anderson), an analysis of The Cancer Genome Atlas  
 (TCGA) was undertaken that revealed that elevated Amot 130 transcript levels in 
breast cancer tumors correlate with a poor patient survival hazard ratio 1.13 (p < 
0.01). This is consistent with reports which found elevated total Amot levels were 
linked with more aggressive breast tumors of higher grade from patients with a 
poorer prognosis and reduced survival [130,131]. Additionally, using SAGE tag 
analysis from K. Polyak, PhD. of the Dana Farber Cancer Institute, we observed 
that total Amot transcripts were elevated in tumor cells and specifically those with 
increased CD44 surface expression which is associated with a cancer stem cell  
signature (Fig 1-11).   
Amot 130 is a direct binding partner of YAP1 and TAZ. The first 171WW208 
domain of YAP1 associates with the 106LPTY109 and 239PPEY242 domains of Amot 
p130. It appears that the second WW domain of YAP1, binds selectively to the 
second PPEY domain of Amot p130. Amot 130 can simultaneously associate 
with two WW domains of YAP1 (PPEY/WW; LPTY/WW), it only forms an 
association with TAZ at one domain site (PPXY/WW) [132,133]. This fact, in 
addition to the functional redundancy between the YAP1 and TAZ coactivators, is 
mostly responsible for the primary focus of study on the Amot p130 and YAP1 
interaction. The highly conserved ACCH domain among the Amot family allows 
these proteins to heterodimerize with one another [128,134]. The dimerization of 
Amot130 and Amot 80 greatly impacts the function and localization of Amot 130 
which, in turn, affects the trafficking of polarity proteins and YAP1. Amot has   
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Figure 1-11. The levels of Amot transcripts indicate a potential signature 
for identifying invasive breast tumors versus normal tissue. In 
collaboration with K. Polyak (Dana Farber Cancer Institute), the relative levels 
of transcripts for Amot were determined by SAGE analysis from primary 
mammary cells derived from normal or invasive cancer tissue following cell 
sorting on CD24 and CD44 (stem-like) status. Sample size is indicated. SEM. 
p ≤ 0.05. Data from K. Polyak, PhD. of the Dana Farber Cancer Institute. 
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been found to be required for ERK induced growth of breast cancer cells. MCF7 
cells infected with a cerulean fluorescent protein (CFP) tagged-Amot 80 plasmid 
resulted in a 2.2 fold increase in the levels of [3H] thymidine incorporated into 
nucleic acids as compared to control, indicating a robust enhancement of 
proliferation. When MCF10A cells overexpressing Amot 80 were cultured in 
Matrigel©, the resulting mammary acini lacked a hollow lumen and exhibited 4-
fold greater cross-sectional area when compared to control cells [13]. Ectopic 
expression of Amot 130 was found to render mammary acini with reduced cross-
sectional area [138], however, in unpublished data from our lab, the 
coexpression of Amot 130 and Amot 80 resulted in cells that showed enhanced 
growth and failed to form a polarized acini structure verses control cells. 
Likewise, total Amot knockdown resulted in cells that lacked any growth in 
Matrigel© [12]. Taken together, these data suggest that the dimerization of the 
Amot isoforms is required for YAP1 nuclear translocation and that Amot 80 
functions to dominantly redirect the Amot130/YAP1 complex resulting in YAP1 
nuclear accumulation.  
Amot 130 also inhibits YAP1 by reducing its stability through coupling it to 
the atrophon 1 interacting protein 4 (AIP4) E3 ubiquitin ligase. This enhances 
YAP1 ubiquitination and degradation [135]. Importantly, phosphorylation of 
Amot130 by LATS1/2 is required for Amot 130 to bind both to YAP and to AIP4. 
Consistent with the phosphorylation of Amot 130 being essential to turn on its 
anti-YAP1 activity. MCF10A cells expressing a mutated form of Amot 130, 
(S175A), which cannot be phosphorylated by LATS1/2, exhibited unrestricted cell 
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growth as compared to cells expressing wild type Amot 130 when grown in 
Matrigel©. Consistent with this being due to increased YAP1 activity, cells 
expressing Amot 130 S175A exhibited 1.8-fold increased CTGF transcript levels 
verses control cells and 3.6 fold greater transcript levels of CTGF than cells 
expressing WT Amot 130 [136]. 
While several studies show that the p130 and p80 isoforms of Amot 
dictate opposing effects on the activity of YAP1/TAZ, very little is understood 
about how their expression is controlled [133,135-139]. Limited work has found 
that Amot 130 and Amot 80 are splice isoforms. However, it is possible that they 
are driven by two separate promoters that lie at different positions in the AMOT 
gene. Thus, the current literature on Amot leaves many questions unanswered. 
Due to their unique roles within the cell, understanding the expression of Amot 
requires a deeper investigation of how these two isoforms are differentially 
regulated.  
 
1.9. The major questions and hypotheses of this work 
 The work comprising this dissertation seeks to understand the 
mechanisms that control the expression of Amot in order to better comprehend 
how breast cancers induce increased levels of Amot in breast epithelial cells to 
promote the transition from DCIS to IDC. We hypothesize the following: 
Inflammation in the breast drives a DCIS to IDC transition through the secretion 
of IL-6 from inflammatory cells in the stroma, which functions to disrupt 
intracellular polarity by inactivating HIPPO signaling and foster the nuclear 
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translocation of YAP1 to promote growth. We postulate that the inactivation of 
HIPPO signaling is not through the kinase component, but through the activated 
expression of the Amot isoforms. To answer these broad questions, we 
addressed the following more specific points: 1. Associate the histologic 
measures of Amot protein levels and subcellular localizations with reports of 
enhanced levels of Amot transcripts in breast tumors. 2. Define the AMOT gene, 
its regulatory region(s), the promoter elements that control its transcription, and 
the manner in which the unique isoforms are expressed. 3. Define the impact of 
inflammatory cytokine induced signaling on Amot expression. 4. Determine the 
importance of Amot as an effector of inflammatory induced cell dedifferentiation 
and proliferation. 5. Identify the key factors in inflammatory based signaling that 
induce Amot transcription.   
Our novel hypothesis seeks to illuminate the role of tumor-associated 
inflammation in driving the loss of intracellular polarity in mammary epithelial cells 
to facilitate DCIS to IDC transitions. The accomplishment of our aims laid out 
above will establish the Amot HIPPO adapter proteins as key players in DCIS to 
IDC transitions. This work has the potential to underlie the use of the Amot 
proteins as biomarkers to predict DCIS to IDC transitions at the time of a DCIS 
diagnosis, and perhaps preclude unnecessary surgeries. Moreover, this work 
may launch anti-Amot drug discovery efforts in the prevention of DCIS to IDC 
transitions. 
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CHAPTER 2: MATERIALS AND METHODS 
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*Please Note: This chapter contains the detailed instructions for the techniques 
common to multiple chapters within this dissertation. Chapter-specific methods 
and materials are detailed further within the chapters. 
 
Mammalian Cell Culture  
Cell lines were thawed from -80 oC (freezer) and/or -196 oC (liquid 
nitrogen tank) via incubation in 37 oC for a duration of no more than 5 minutes. 
Cells were then diluted with 2 milliliters (mLs) of complete DMEM culture media, 
transferred to a 15 mL conical tube, and then centrifuged at room temperature 
(R.T.) for 1.5 minutes at 1500 rotations per minute (rpm). The supernatant was 
removed and cells were re-suspended into 10 mLs of their respective culture 
medium.  The suspended cells were transferred into 10 centimeter (cm) culture 
plates for stock culture. Michigan Cancer Foundation-7 (MCF7), MD Anderson 
MetaBlastic-468 (MDA-MB-468), Human Epithelial Kidney 293 Tert-immortalized 
(HEK 293T), SKBR3, U373, and C2C12 cells were cultured in Complete DMEM 
(10% FBS, 1% (v/v) penicillin/streptomycin, and Dulbecco’s Modified Eagle 
Medium (DMEM)). Michigan Cancer Foundation 10A (MCF10A) pre-tumorigenic 
cells were cultured in 250 mLs Hams-F12, 250 mLs DMEM, and supplemented 
with 50 micrograms/milliliter (µg/mL) Bovine Pituitary Extract (BPE) (Hammond, 
1078-NZ), 0.5 µg/mL hydrocortisone, 5 µg/mL human insulin, 10 
nanograms/milliliter (ng/mL) epidermal growth factor (EGF), and 100 ng/mL 
cholera toxin.  Cells were incubated at 37 oC with 5 % CO2 (v/v). Cells in culture 
were monitored at least once every two days, and were split as needed. To split 
cells grown in culture, the following reagents were prewarmed for a duration of 
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20 minutes at 37 oC: 1X phospho-buffered saline (PBS), 1X trypsin, Complete 
DMEM (or respective media). The media of the cells to be split was aspirated 
and replaced with a warm 2.5 mL PBS wash, which was then aspirated and 
replaced with 2.5 mL 1X trypsin. Cells were then returned to the 37 oC incubator 
for a duration of 5 minutes, or until cells had visibly lost adherence. The cell-
trypsin solution was then resuspended in Complete DMEM (or respective media) 
at a 1:1 ratio and transferred into a labelled 15 mL conical tube.  The cell solution 
was centrifuged at room temperature for 1.5 minutes at 1500 rpm. The 
supernatant was removed and cells were re-suspended at the desired dilution 
into 10 mLs of their respective culture medium.        
 
Polyethylenimine (PEI) Transfection 
 DNA was introduced into adherent eukaryotic cells at a ratio of 1 μg of 
plasmid DNA per 200,000 cells. DNA was diluted into 1 mL of prewarmed serum-
free DMEM, and (2μg/mL) polyethylenimine (PEI) was added at a ratio of 0.5 μL 
PEI per 1 μg of DNA. Once added, the solution was vortexed for 5 seconds and 
allowed to incubate at ROOM TEMPERATURE for a duration of five minutes 
prior to adding to a plated of adhered cells. Cells were incubated in transfection 
media at for 12-18 hours at 37 oC with 5 % CO2 (v/v).    
 
Lentiviral Transduction 
 HEK 293T cells were plated at 4 million cells into a 10 cm plate and 
allowed to adhere overnight prior to transfection with 20 μg of target lentiviral 
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DNA plasmid, 10 μg of pMDLg-RRE, 6 μg pCMV-VSVG, 5 μg pRSV-Rev, and 25 
μL PEI (2 μg/mL). Cells were incubated with transfection medium for a duration 
of 18 hours, and subsequently replaced with 7 mLs of Complete DMEM to collect 
secreted viral particles. Virally conditioned media was collected and replaced 
again with 7 mLs of Complete DMEM every 24 hours for a duration of 2 days. 
Virally conditioned media was centrifuged at 1500 rpm for 4 minutes and the 
supernatant was collected. Polybrene (5 mg/mL) was added to viral media at a 
ratio of 3 μL polybrene: 1 mL viral media. Viral media was stored at 4 oC for no 
longer than 2 weeks. Prior to infection, target cells were plated at 1 million cells 
into a 10 cm plate and allowed to adhere overnight. The target cells were then 
incubated in viral media for a duration of 6 hours. Target cells were then split 
within 24 hours of the completion of the viral incubation to encourage cell division 
and expression of the target plasmid. A representative population of infected 
cells was harvested at least 48 hours after infection to confirm expression via 
immunoblot.      
 
pGL3 Luciferase Reporter Assays 
 HEK 293T cells were plated (200,000/well) into a 12 well dish and allowed 
to adhere overnight. Cells were transiently transfected with 0.25 μg TK-Renilla as 
a transfection control, and 0.25 μg full Amot, serially deleted Amot, or SP1 motif 
site-mutated promoter plasmids. Luciferase was allowed to accumulate for a 
duration of 20 hours before cell lysis (200 uL volume per sample) in Promega 
Luciferase 5X Lysis Buffer (diluted in water). Samples were processed per 
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manufacturer’s instructions for Dual-Luciferase Reporter Assay System 
(Promega, TM040). A dual luminometer (BioSystems) was utilized to analyze all 
samples. Data are presented as average ratios of Firefly luciferase 
measurements over control Renilla measurements.  
 
Immunoblotting 
 Proteins were harvested in radioimmunoprecipitation assay RIPA buffer 
(25mM Tris 7.4, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 0.5% 
sodium deoxycholate, and 1X Triton X) quantified using a bicinchoninic acid 
(BCA) assay, normalized and ran out on and SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) in running buffer at 100 volts until the dye front 
reached the bottom of the gel. The proteins in the gel were transferred onto a 
0.45 micron nitrocellulose membrane (Protran) in transfer buffer at 24 volts for a 
duration of 45 minutes. The transferred membrane was then probed with primary 
antibody overnight at 4 °C (Table 2-1) and anti-rabbit or anti-mouse secondary 
antibodies (Odyssey) diluted 1:50,000 for a duration of 30 minutes at room 
temperature. All primary and secondary antibodies were diluted in tris-buffered 
saline with Tween (TBST). The membrane was then imaged on a Licor imager.   
 
Table 2-1. Primary antibodies used in the immunoblots within this dissertation. 
Primary 
Antibody 
Antigen(s) 
Detected 
Obtained from Dilution (in TBST) 
476 Final Bleed; 
Affinity Purified; 
α-Rabbit 
Amot p130; 
Amot p80 
Wells Lab Custom 
Antibody 
1:1000 
Yap1; α-Mouse 
Yes Associated 
Protein 1 
Abnova 
H00010413-MO1 
1:1000 
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Phospho-Yap; α-
Rabbit 
Yap1 Ser127 
Cell Signaling, 
4911S 
1:1000 
Taz; α-Mouse 
Transcriptional 
co-activator 
with PDZ-
binding motif 
BD Biosciences, 
560235 
1:1000 
Stat3; α-Mouse 
Signal 
transducer and 
activator of 
transcription 3 
Cell Signaling 1:1000 
Phosph-Stat3; α-
Rabbit 
Stat3 Tyr705 Cell Signaling 1:1000 
LATS 1; α-Rabbit 
Large Tumor 
Suppressor 1 
Bethyl, A300,-
477A 
1:1000 
Phospho-LATS 1; 
α-Rabbit 
LATS1 Ser909 
Cell Signaling, 
9157S 
1:1000 
Sp1; α-Mouse 
Specificity 
Protein 1 
Santa Cruz 1:1000 
GAPDH; α-Mouse 
Glyceraldehyde 
3 phosphate 
dehydrogenase 
Millipore, MAB374 1:20,000 
M2; α-Mouse Flag Tag Sigma, F3165 1:10,000 
 
RNA Extraction 
 The media from cells to be extracted was aspirated and replaced with a 1 
mL PBS wash, and then again was aspirated. Cells were then treated with Tri-
Reagent LS (Sigma) at a ratio of 500 μL per 1 million cells and the solution was 
transferred to a labelled 1.5 mL microcentrifuge tube. The cell solution was 
allowed to incubate at room temperature for 5 minutes before the addition of 200 
μL of chloroform. Tubes were vortexed and centrifuged at a rate of 14,000 rpm at 
4 oC for 10 minutes. The upper aqueous phase containing RNA was transferred 
to a fresh microcentrifuge tube and diluted 1:1 in isopropanol. Tubes were 
vortexed and centrifuged at a rate of 14,000 rpm at 4 oC for 10 minutes. The 
supernatant was discarded and the pellet containing RNA was washed twice in 
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70 % ethanol; a centrifugation step at a rate of 14,000 rpm at 4 oC for 10 minutes 
proceeded each wash. Once the final supernatant was discarded, the pellet was 
allowed to dry at room temperature for a duration of 5 minutes. The RNA was 
then diluted in 30 μL of deionized water and the concentration (ng/mL) was 
measured via Nanodrop©.    
 
Complementary DNA (cDNA) synthesis 
 Freshly extracted RNA was employed to synthesize complementary DNA 
(cDNA). A recipe including 5 μg RNA, 2 μL oligo deoxy-thymine (oligo dT) (for 
the amplification of regions near the 3’ end of the gene product) or random 
hexamers (for the amplification of all other regions of the gene product), and 4 μL 
deoxy-nucleoside triphosphates (dNTPs) risen up to a total volume of 24 μL was 
incubated at 65 oC for a duration of 5 minutes. The following reagents were then 
added to the solution: 10 μL ddI water, 4 μL 10X reverse transcriptase buffer, 2 
μL Superscript II reverse transcriptase. Tubes were then incubated at 50 oC for a 
duration of 1 hour. The concentration of the resulting cDNA was measured via 
Nanodrop©. Sample concentrations were normalized to a standard of 300 ng/mL.   
 
Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) 
 Primer sets were designed to satisfy requirements for PCR with SYBR 
green polymerase, with melting temperatures between 59 oC-61 oC and amplicon 
lengths between 70-150 base pairs. These primers were then diluted to a 
concentration of 100 μM stock stored at -20 oC, with a working stock 
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concentration of 10 μM stored at 4 oC. The recipe for each PCR reaction required 
5 μL cDNA  (300 ng/mL), 10 uL 2X SYBR Green Master Mix (BioLine), 1 μL 
forward and 1 μL reverse primers (10 μM) and 3 μL ddI water. Reactions were 
plated into a 96 well clear PCR plate, covered with a clear adhesive film, and 
centrifuged 4000 rpm at 4 oC for 10 minutes. The plate was then loaded into the 
Realplex2 Gradient Mastercycler (Eppendorf). All crossover threshold values of 
target genes were normalized to GAPDH or 18S ribosomal RNA.     
  
Fixed Cell Imaging  
 Cells (200,000) were plated on acid washed glass coverslips coated in 
fibronectin and collagen distributed in 12 well plates (Corning) and allowed to 
adhere overnight. Media was removed and cells were harvested in a 4% 
paraformaldehyde (PFA) wash for a duration of 5 minutes at 4 degrees Celsius.  
Slides were then incubated at 4 degree C in blocking buffer (5% bovine serum 
albumin/0.2% saponin in PBS) for a duration of 1 hour. Coverslips were 
incubated in YAP1 anti mouse primary antibody (Abnova) diluted between 
1:1000 in blocking buffer for 1 hour and in 488 anti-mouse secondary antibody 
(Alexa Fluor) diluted 1:500 for 30 minutes (in the dark). Slides were rinsed in 
blocking buffer and DDI before removal from the 12 well dish, flipping over and 
placed onto a glass slide covered in ProLong Gold mounting media. Slides were 
allowed to dry overnight in the dark prior to imaging. 
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Fluorescent Microscopy  
 Epifluorescent images were acquired using structured light via an 
Apotome on a Zeiss Axio ObserverZ1. This technique is described in greater 
detail in Chapter 3 of this dissertation.  
 
Quantification of Immunofluorescent Imaging 
 Zen image processing software (Zeiss) was used to quantify the average 
pixel area and intensity per nuclei of each antigen. Tissue structures were 
isolated and quantified, thereby eliminating the hollow lumen from the calculation.  
 
Analysis of The Cancer Genome Atlas (TCGA) 
 Level 1 TCGA analysis was completed by Dr. Cristina Ivan at University of 
Texas MD Anderson Cancer Center of Houston, TX, which provided us the 
correlations of Amot transcript levels to its corresponding hazard ratio and the 
breast tumor associated transcripts in over 700 breast tumor tissue samples. 
Raw data was analysed and compiled into graphic form in Microsoft Excel.  The 
results shown here are in whole or part based upon data generated by the TCGA 
Research Network: http://cancergenome.nih.gov/.   
 
Statistical Analysis 
 Statistical analysis was completed using Microsoft Excel software. 
Precision was displayed as either standard deviation (S.D.) or standard error 
(S.E.M.).  S.D. was used unless a high sample size called for the use of a 
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weighted mean, in which S.E.M. was employed. Significance was tested using a 
two-tailed, two-sample of unequal variance Student’s t-test. A significance 
threshold was maintained at p < 0.05.  
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CHAPTER 3: LED PHOTOBLEACHING REDUCES AUTOFLUORESCENCE 
AND ENHANCES ANTIGEN RETRIEVAL OF PARAFFIN EMBEDDED HUMAN 
BREAST TISSUE SECTIONS 
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3.1 Prologue 
The first point to address in our project was to associate the histologic 
measures of Amot protein levels and subcellular localizations with reports of 
enhanced levels of Amot transcripts in breast tumors [132]. Therefore, we set out 
to investigate the levels and subcellular localization of the Amot proteins in 
human breast tissue samples. The decision to use fluorescence based detection 
methods held the promise of several advantages including: A) the ability to image 
multiple antigens per slide, B) the ability to quantify signals for each channel with 
little interference from other channels, C) the much greater sensitivity of 
fluorescence detection verses standard IHC based methods, and D) the ability to 
image multiple planes of the same field in the form of a Z-stack. However, a 
barrier for analyzing samples using fluorescent methods was the significant 
autofluorescence detected in archival paraffin embedded tissues following 
standard fixation and permeabilization methods.  To overcome this, we innovated 
a cost and time efficient technique to degrade the high degree of 
autofluorescence commonly associated with human mammary tissue. 
 
3.2 Introduction 
The ability to define the concentration and 3-dimensional localization of 
multiple antigens in a common tissue sample would allow a much deeper 
understanding of the molecular changes that associate with breast cancer 
formation and progression. Immunofluorescent (IF) labeling has the potential to 
be a superior method to standard immunohistochemically (IHC) techniques that 
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are mainly used by pathologists (Table 3-1) [140,141]. IHC became the standard 
method for labeling breast cancer markers in biopsies in 1999 after succeeding 
the use of ligand binding biochemical assays. The IHC method proved more 
specific and better able to analyze samples of smaller volume [142,143]. 
Additional technological innovations have since been made in the field of 
fluorescence microscopy to overcome the limitations of IHC. For instance, IHC is 
confined to analyzing a single antigen in 2-dimensions. IHC labeling also 
prohibits the isolation of antigen staining from hematoxylin and eosin (H&E) 
staining, resulting in an increased difficulty in the quantification of antigen levels. 
This also prohibits the study of multi-antigen association and co-localization in 
tissue samples [144]. In contrast, immunofluorescent (IF) labeling allows the 
imaging of multiple antigens in a single sample simultaneously due to the ability 
to detect each antigen using a different excitation and emissions spectra. This 
provides for the determination of the localization of multiple antigens in relation to 
each other.  Additionally, the detection via different emission spectra also allows 
for the ability to view and quantify isolated images of each distinct antigen [145]. 
Despite all of the advantages of IF staining, this technique presents distinct 
complications, particularly when it is applied to the analysis of para-formaldehyde 
(PFA)-fixed tissue sections. Because the overwhelming majority of archival tissue 
is fixed with PFA, it is vital to develop analysis methods that are compatible with 
PFA fixation [146]. However, this embedment technique generally results in 
significant autofluorescence between the wavelengths of 450-550 nm [147,148]. 
 
 
  
47 
Table 3-1. Comparison of the advantages and disadvantages between different 
antigen staining techniques. 
 
Immunohistochemical 
Staining 
Immunofluorescent 
Staining (Epifluorescent 
Microscope) 
Total Number of 
Simultaneous Antigen 
Detection 
1 3 
Capable of 3-
Dimensional Imaging? 
No Yes 
Capable of single 
antigen distinguishable 
quantification? 
No Yes 
Autofluorescence 
resulting in high 
background 
No Yes 
 
Autofluorescence refers to the inherent and nonspecific fluorescent 
spectra emitted from organic tissue. This results from naturally occurring, 
fluorescence-emitting protein structures, tissue components, and embedment in 
aldehyde fixatives [147,149-155]. Degrees of autofluorescence varies between 
different types of tissues. Autofluorescence is caused by many sources including 
lipofuscins, collagen, flavins, reticulin fibers, elastin, NAD(P)H, and proteins with 
high concentrations of tyrosine, tryptophan, and phenylalanine, all emitting 
natural fluorescence at varying wavelengths [155]. There are a number of 
organic properties that contribute to the ability of a molecule to reflect and/or 
refract light, including: the presence of electron donating groups, aromatic rings, 
chiral centers, and compounds that contribute to peroxide formation [156, 157]. 
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Tissue-type specific differences in metabolic rates-with regard to co-enzymatic 
redox carrier activity (flavins, NADPH), red blood cell (RBC) concentration and 
degradation rates, (lipofuscins), and stromal structure can result in significant 
autofluorescence [157]. 
Autofluorescence becomes a major impediment to imaging tissues as it 
clouds the ability to distinguish the signal emitted from a labeled antigen from the 
fluorescence-emitting components in the tissue. Additionally, as tumor cells 
possess elevated metabolic rates and thus increased concentrations of flavins 
and NADPH, the degree of tumorigenicity also dramatically contributes to 
autofluorescence. Particularly in mammary tissue, autofluorescence has long 
been used as a clinical tool for detecting tissue malignancy, as tumor tissue 
composition differs drastically from that of benign tissue [79,156].   
Many techniques have been developed as single remedies to reduce the 
level of autofluorescence in tissues for the purpose of IF antigen detection. Such 
methods include short wave ultra-violet (UV) photobleaching, chemical 
treatments, digital background reduction, and image processing methods by 
confocal laser imaging [151-155,157,158]. However, we found that these 
methods were either ineffective in our samples, were highly damaging to the 
tissue, or required imaging equipment that is outside of the budget of most 
biomedical research laboratories. We therefore set out to find methods to combat 
autofluorescence in mammary tissue that could be applied to epifluorescence-
based focal imaging.  
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The autofluorecence of mammary tissue occurs predominantly between 
400 and 500 nanometer wavelengths.  This greatly impedes the imaging of these 
tissues in the green fluorescent protein (GFP) channel, a key excitation and 
emission spectra used for epifluorescence-based imaging. Methods to reduce 
this autofluorescence such as long term exposure to short-wave UV 
photobleaching has the deleterious effect of damaging the tissue structure. 
Chemical pre-treatments such as sodium borohydride, which is reported to 
reduce autofluorescence of several types of tissues [159], in our hands was 
ineffective and has been reported by others to enhance autofluorescence in 
mammary tissue (Fig 3-1).  Confocal laser image processing cannot be applied 
to standard epi-fluorescent imaging microscopes.    
After analyzing the absorption and emissions spectra of autofluorescing 
compounds in mammary tissue, we realized that they mainly absorbed around 
450 nm. Further, the recent development of light emitting diodes (LEDs) that emit 
with high intensity and low heat at this wavelength suggested that they may be 
appropriate for photobleaching mammary tissue with minimal tissue damage. 
This initial series of observations and research resulted in the development of a 
simple, rapid, and inexpensive method of mammary tissue immunofluorescence 
staining that focuses on: 1. Reducing mammary-tissue specific auto-
fluorescence; 2. minimizing residual background signals via long-wave LED 
photobleaching and optimized epi-focal image processing.  
 
3.3. Materials, Methods, and Results 
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Figure 3-1. Exposure of mammary tissue sections to sodium 
borohydride had no effect on autofluorescence reduction.  A. 
Mammary tissue sections were subjected to treatment with 10 mM NaBH4 
for a duration of 24 hours prior to deparaffinization and then stained with 
Hoescht dye. Fluorescent epifocal imaging of each section was performed 
using the 40X W objective and a constant exposure time of 1S in the GFP 
channel. B). Zen immunofluorescent quantification software was used to 
analyze the average GFP channel mean intensity normalized to the 
number of nuclei. N=3; Standard Deviation; p < 0.01. 
Tissue Sections.   
 
 
 
  
A 
B 
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Tissue Sections 
Tissue sections were PFA-fixed 5 µm thick sections mounted onto glass 
slides. We acquired malignant mammary tissue sections from the IUSM Simon  
Cancer Center.  Additionally, we acquired 60 slides from fourteen blocks of the 
IUSCC Tumor MicroArray. This was compiled by members of the breast cancer 
working group.  
 
Slide Processing   
After testing multiple durations, it was determined that the optimal 
conditions were a 24 hour exposure of tissue slides to a 90W industrial blue 
wavelength) LED light (LED Wholesalers) with a 1980 luminous flux intensity at a 
distance of 0.5 centimeters (cm) from the light source on a foil background (Fig 
3-2). While this was carried out at room temperature, the temperature on the 
slide surface was 65°C. This long treatment with relatively low heat visibly melted 
the paraffin and as discovered below is thought to also contribute to better 
antigen retrieval.    
 
Deparaffinization and Rehydration:  
Sections were treated with xylene for a duration of 5 minutes and then 
rehydrated with two 3-minute washes of 100%, 95%, 80%, and 70% EtOH 
solutions and finally rinsed three times with ddH2O. 
Antigen Retrieval, Blocking, and Antibody Staining:  
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Figure 3-2. Exposure of mammary tissue sections to 452 nm LED light 
reduces autofluorescence in the GFP channel. Mammary tissue sections 
were subjected to 0, 12, and 24 hr exposures to 452 nm LED light and then 
stained with Hoescht dye. A). Fluorescent epifocal imaging of each section 
was performed using the 40X W objective and a constant exposure time of 1S 
in the GFP channel.  B). Zen immunofluorescent quantification software was 
used to analyze the average GFP channel mean intensity normalized to the 
number of nuclei. N=3; Standard Deviation; p < 0.01. 
  
 
 
A 
B 
  
53 
Sections were subjected to a 20 minute 10 mM Na3C6H507 boil using a 
1100 watt, 2450 MHz microwave (Whirlpool) at full power, with intermittent 
pauses every 2 minutes to replace the displaced solution with ddH2O. Sections 
were then placedin a 5.0 % / 0.01 % bovine serum albumin (BSA) / saponin 
phosphor-buffered saline (PBS) blocking buffer solution for one hour at room 
temperature. In addition the 24 hour heating of the sample to 65 degrees 
produced by the LED at the slide surface was found to reliable enhance the 
specific signal from the antigen and it is therefore postulated to enable antigen 
retrieval. This matches our findings and the findings of other groups that have 
shown that heat disrupts aldehyde cross-linking that can block epitope availability 
(Fig. 3-3) [160]. Slides were then incubated in primary antibody (Table 3-2) 
diluted in blocking buffer for 1 hour at room temperature and in anti-rabbit or anti-
mouse 594 or 488 nm secondary antibodies (Alexa Fluor) diluted 1:500 for 30 
minutes (in the dark). Nuclei were underwent a 9 minute incubation in Hoescht 
dye diluted 1:3000 in blocking buffer. Slides were then rinsed in blocking buffer 
and DDI before drying in the chemical hood for 5 minutes. Once dry, glass 
coverslips were adhered to the slides using ProLong Gold mounting media. 
Slides were allowed to dry overnight in the dark prior to imaging. 
Table 3-2. Primary antibodies used in immunofluorescence staining in Chapter 3. 
Primary 
Antibody 
Antigen(s) 
Detected 
Obtained from 
Dilution (in 
Blocking Buffer) 
475 Bleed 2 
Affinity Purified; 
α-Rabbit 
Amot p130; 
Amot p80 
Wells Lab Custom 
Antibody 
1:500 
Β-Catenin; α-
Mouse 
Β-Catenin BD Biosciences, 1:1000 
9E10; α-Mouse Myc 
Cell Signaling, 
2272S 
1:10,000 
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Figure 3-3. The heat produced from the LED light 
functions to enhance antigen retrieval of human 
mammary tissue. Mammary tissue sections were 
subjected to 24 hr exposures to either 65°C heat or 452 
nm LED treatments and then immunolabelled for β-
catenin to demonstrate effects on antigen specificity.      
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Microscopic Imaging:  
All imaging was carried out using a 4 objective, 6-filter enabled Zeiss  
AxiObserver Microscope with epifluorescence capabilities. The capochromat 40X 
water immersion objective was used for image acquisition. Filter sets and fluor 
combinations consisted of the high efficiency YFP, DsRED, and DAPI filter sets. 
Confocal-like imaging was acquired using an apotome attachment (Fig 3-4; 3-5)     
 
Image Quantification:  
Mean average signal intensity was quantified using the Zen image 
quantification software packages, an accompaniment to Zeiss Axiovision image 
acquisition software. Mean average pixel intensity was used to measure protein 
expression in the tissues. The number of nuclei present in each analysis field 
were counted by hand. Mean average signal intensity values were the 
normalized to the number of nuclei present in the measured area.  
 
Statistical Analysis: 
Immunofluorescent average signal intensities normalized to number of 
nuclei were presented as the means ± S.D. P-values were calculated by an 
unpaired two-tailed t-test.  A significance threshold was maintained at p < 0.05. 
 
Optimization of custom Wells Lab Amot antibody for IF:  
The antigen specificity of custom Wells Lab Amot antibody (475 Bleed 2; 
affinity purified (475 B2 AP) was first tested via overexpressing the MYC-tagged 
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Amot in fixed-cell IF imaging. A MYC-tagged construct containing the insert 
coding for Amot or an empty insert was transfected via PEI into in MCF7 cells 
that were cultured on glass coverslips. After an 18 hour incubation in transfection 
media, coverslips were fixed via incubation in a 4 % PFA solution at 4°C for a 
duration of 5 minutes. This was followed by three 5-minute PBS washes and a 1-
hour long incubation in blocking buffer at room temperature. Coverslips were 
then incubated with a primary antibody solution containing MYC (dilution 
1:10,000) and 475 B2 AP at the following dilutions: (1:100, 1:250, 1:500, and 
1:1000). The corresponding imaging experiment compared the staining of the 
MYC antibody to the Amot antibody and found that the IU 475 B2 AP antibody 
against Amot was specific to the Amot protein and that the optimal dilution for 
use with IF protocols is 1:500 (Fig 3-4A) (other dilutions not shown). Epitope 
blocking experiments were employed to validate the specificity of antibodies for 
their indicated antigen. Epitope blocking involves incubating the antibody with 
protein constituting the epitope originally used to create the antibody at a 1:1 
ratio for a duration of 4 hours.  This solution, or a vehicle solution containing a 
control epitope, was then applied to the tissue section, replacing the primary 
incubation step in the protocol above. The corresponding imaging experiment 
compared the staining of the epitope blocked antibody to that of the control in 
order to determine viable antigen specificity of each antibody (Fig 3-4B).  
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Figure 3-4. The Wells lab custom Amot antibody selectively 
binds the Amot-specific epitopes. A. A rabbit polyclonal antibody 
raised against Amot was affinity purified and used to probe breast 
cancer cells expressing a myc-tagged Amot 130 construct. Co-
staining of anti-Myc and Anti-Amot antibodies shows the specificity 
of the anti-Amot antibody. B. The Amot antibody was incubated 
with a 5-fold excess of purified antigen or control block prior to 
staining human breast tumor tissue.   
A 
B 
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3.4. Discussion 
LED exposure reduces autofluorescence of mammary tissue that was 
primarily seen between 450-510 nm. Sections subjected to LED exposure at 
durations varying between 0 and 24 hrs were stained for nuclei without antigen 
retrieval and imaged. A reduction of the autofluorescence in the 488 nm channel 
are clearly seen between the photobleached and non-photobleached samples 
(Fig 3-2A). Consistently, the mean average intensity showed a direct negative 
correlation with the length of LED exposure (Fig 3-2 B).  
 Residual green and red autofluorescence is virtually undetectable with the 
use of longer wavelength filters. In addition to the autofluorescence reduction 
resulting from the LED exposure, residual autofluorescence can be eliminated by 
using the high efficiency (HE) 526/594 yellow fluorescent protein (YFP) / far red 
(DsRED) filter sets verses 488 green fluorescent protein (GFP) / 456 texas red 
(TR) filter sets.  The HE 526/594 filter sets also eliminate any bleed-through 
between channels.  
Combining a 24hr LED exposure and imaging with 526/594 filter sets 
resulted in highly specific immunofluorescent imaging of normal and triple 
negative mammary tumor sections. These sections following exposure to a 24 hr 
LED treatment, were deparaffinized and labelled with a mouse monoclonal 
antibody against Beta-Catenin and the IU 475 bleed 2 AP rabbit polyclonal 
antibody using the protocol described above. Beta-Catenin (green), Amot (red), 
and nuclei (blue), can be seen to distinctly localize at cell junctions, punctae, and 
nuclear structures respectively (Fig 3-5). Thus, three channels were able to be 
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Figure 3-5. LED photobleaching reduces mammary tissue 
autofluorescence at an optimized duration of 24 hrs. Mammary tissue 
sections were exposed to a photobleaching treatment with a high intensity blue 
(single wavelength at 450nm) Light-Emitting Diode (LED) semi-conductor light 
source for an optimized duration of 24 hrs prior to the de-paraffinization and 
compared to a no treatment control. Both treated and untreated sections were 
then immuno-labeled with Amot α-Rabbit (Wells Lab 1:500) and β-catenin α-
Mouse (Cell Signaling 1:1000) primary antibodies, Alexas 546 TR α-Rabbit 488 
α-Mouse (Invitrogen 1:500) secondary antibodies. Nuclei were stained with 
Hoescht (1:500). All labels were diluted in blocking buffer (PBS/5% BSA/1% 
saponin). The three fluorescent signals were each excited with the Zeiss 
epifluorescent YFP, DsRed, and DAPI filter sets. 
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imaged simultaneously using epifocal imaging, with antigen specificity that is only 
comparable to that of confocal imaging.  This comprehensive method opens up 
wide possibilities for breast cancer groups that are limited to epifocal microscope 
immunofluorescent imaging. The ability to examine up to three fluorescent 
channels simultaneously can give us substantial insight in many aspects of 
protein behavior in normal verses tumorigenic human mammary tissue.    
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CHAPTER 4: AMOT EXPRESSION IS HIGHEST IN BREAST TISSUE THAT IS 
UNDERGOING A TRANSITION FROM DCIS TO IDC, AND OCCURS IN 
MULTIPLE SUBCELLULAR LOCALIZATIONS 
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4.1. Introduction  
 In 2006, Jiang et al. connected the levels of mRNA transcripts of Amot 
family members with clinical features and outcomes of breast cancer tissue in 
which they were measured. The transcripts analyzed included TOTAL AMOT, 
AMOT L1, and AMOT L2. This study was the first to identify that elevated TOTAL 
AMOT (Amot 130 and Amot 80) transcript levels significantly associated with 
higher tumor grade, increased metastasis of breast cancers, and poor survival. In 
addition, Lv et al. 2015 found consistent results through immunohistochemical 
(IHC) analysis. The comparison of normal breast tissue to breast tumor tissue by 
quantitative real time PCR (RT-PCR) revealed a nearly 3-fold elevation in AMOT 
mRNA levels in the tumor tissue (p ≤ 0.05) when compared to normal breast 
tissue. The transcript levels of AMOTL1 and AMOTL2 showed no correlation with 
tumor tissue verses normal or with any clinical features of particular tumors.  
The comparison between histological subtypes ductal and lobular 
carcinoma in situ (DCIS and LCIS) yielded in a nearly 2-fold elevation of TOTAL 
AMOT mRNA in DCIS tissue. The significance here lies in the passive nature of 
LCIS; for it is defined simply as the abnormal growth of cells in the lobules of the 
breast and is therefore classified clinically as benign. That Amot levels were 
found to be higher in DCIS tissues over LCIS tissues further demonstrates the 
correlation between Amot expression and breast malignancy [226, 254]. 
Moreover, AMOT mRNA levels also exhibited a 2-fold increase in the more 
aggressive node positive tumors over node negative tumors (p ≤ 0.01) [130]. And 
finally, the comparison between grades I, II, and III breast tumor tissues (Tab 4-
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1) by RT-PCR found the greatest elevation of TOTAL AMOT mRNA  levels (>2-
fold) in grade II breast tumors (p ≤ 0.01), and a moderate (~1.3-fold) elevation in 
grade III breast tumors (p ≤ 0.05) when compared to grade I breast tumors. 
These findings raise the theory that the increase in Amot levels drives early 
phases of tumorigenic progression from low grade tumors to higher grade, more 
aggressive breast tumors.  
 
Table 4-1. Clinical features of breast tumors grades I-III. 
Grade Clinical Features 
I 
Well differentiated cell structure; 
Highly epithelial 
II 
Moderately differentiated cell structure 
 
III 
Poorly differentiated cell structure; 
Highly mesenchymal 
 
Through IHC, Lv et al. found a strong correlation between Amot and the 
proliferation marker Ki67, indicating that Amot is elevated in proliferating tumor 
cells. These investigators also saw an increased staining of Amot protein in 
breast cancer tissues when compared to non-malignant adjacent tissues [131].  
Jiang et al. also saw a association between decreased survival and 
elevated AMOT mRNA levels. The survival of patients was nearly 50 % less than 
mean survival if their tumors showed a 2 fold increase in AMOT mRNA levels (p 
≤ 0.01). Relating AMOT mRNA levels to 10-year clinical outcome data yielded a 
significant correlation (p ≤ 0.03) between elevated AMOT mRNA levels and 
metastasis (>2-fold), whereas no significant correlation occurred between AMOT 
mRNA levels and local recurrence or breast cancer-related death. Kaplan-Meier 
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survivorship curves demonstrated that tumors from patients that exhibited high 
levels of AMOT mRNA correlated with a 12% reduction in survival compared to 
tumors from patients that possessed low levels of AMOT mRNA.  In addition, the 
relation of AMOT mRNA levels to estrogen receptor (ER) status found no 
significant difference in TOTAL AMOT mRNA levels between ER – and ER + 
breast tumors.  
Based on these data, the investigators in Jiang et al. have proposed that 
increased levels of TOTAL AMOT mRNA independently indicate high tumor 
aggressiveness, poor patient survival and a high risk of metastasis [130]. As the 
field has demonstrated a wide divergence in the many functions of the Amot 
proteins with respect to tumorigenicity, and that the function of these proteins 
predominantly depends on cellular polarity status and protein localization, there 
is great importance in studying the expression, localization, and cellular context 
of Amot in breast cancer tissues. The best method for executing this type of 
analysis is the immunofluorescent (IF) staining of human breast tissue samples.   
 
4.2 Methods 
The tissues used for this study included: (1) normal mammary ductal 
epithelial tissue samples from ten healthy female volunteers that were embedded 
in paraformaldehyde and sectioned (5 μm) onto glass slides by the IU Simon 
Cancer Center (IUSCC) at University Hospital in Indianapolis, IN. Slides from a 
block of a tissue microarray (TMA) compiled by the IUSCC consisting of 
surgically excised tumors from 451 patients representing a wide variety of breast 
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cancer subtypes, grades, median 10.3 year patient follow-up data. The block we 
acquired contained 56 breast tumor core samples. All 56 samples were stained 
and imaged, and 24 were found to contain viable tissue.  The remaining 32 core 
samples either were highly concentrated in stromal and adipose tissue with very 
few examples of epithelial tissue, or possessed damage from microtome 
sectioning.  
Slides were processed, stained, imaged, and quantified using the 
protocols detailed in Chapter 3 section 3 (pages 47 - 48) of this dissertation. 
Images were acquired using the following channel specific exposure times: 
DsRed (λ594 nm), 1000 milliseconds, YFP (λ488 nm) (1000 milliseconds), DAPI 
(λ350nm), variable as needed (between 10-30 milliseconds). Representative 
images were compiled and cross-referenced with histological and 10 year patient 
follow-up data.   
 
4.3. Results and Discussion 
 Tumors from twenty-four breast cancer patients consisted of five grade I 
tumors, eleven grade II tumors, and eight grade III tumors. According to 
immunohistochemical staining, four tumors stained negative for the expression of 
estrogen receptor (ER), and seven were negative for the expression of 
progesterone receptor (PR). The human epidermal growth factor receptor 2 
(Her2) status for all twenty-four samples were found negative via fluorescence in 
situ hybridization (FISH) analysis (Table 4-2).  
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Table 4-2. Characteristics of the patient samples studied in this cohort. Tumor 
grade (I-III and hormone receptor status (ER-estrogen receptor/PR-progesterone 
receptor) of tumor samples from the twenty-four patients analyzed in this study 
cohort obtained from IU Simon Cancer Center. Note: all tumor samples are 
negative for human epidermal growth factor receptor 2 (Her2). 
Tumor Grade Hormone Receptor Status 
I 
ER+ / PR- / Her2- 
ER+ / PR+/ Her2- 
II 
ER+ / PR- / Her2- 
ER- / PR+ / Her2- 
ER+ / PR+ / Her2- 
III 
ER+ / PR- / Her2- 
ER+ / PR+ / Her2- 
ER- / ER- / Her2- 
 
In agreement with AMOT mRNA levels in Jiang et al. 2006, we found an 
eleven-fold increase in Total Amot protein expression over normal breast tissues 
in these breast tumor tissues (Fig. 4-1A). Unexpectedly, we saw no significant 
difference in Amot protein levels between ductal and lobular carcinoma tissue, 
nor between tumor grades I-III, which contrasted the findings in Jiang et al. 
published (Fig. 4-1B; 4-2A,B). Our analysis agreed with Jiang that Amot levels 
show no correlation with estrogen receptor status, and furthermore, we also 
found no significant difference in Amot protein expression between PR positive 
and PR negative tumor tissues (Fig 4-3; 4-4). Surprisingly, we saw no difference 
in Amot levels between the less aggressive node-negative tumors and more 
aggressive node-positive tumors (Fig. 4-5). However, we did discover a positive 
correlation between Amot protein levels and metastatic breast tumors, which 
agreed with the mRNA data. Metastatic tumors possessed a nearly 3 fold greater 
expression of Amot than non-metastatic tumors (Fig 4-6A: B). The patients with 
metastatic breast cancer in this cohort had secondary tumors arise in the liver, 
bone, and the soft tissues of the head, face, and neck. Local  
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Figure 4-1. Amot protein levels are elevated in breast tumors when 
compared to normal breast tissues. A. Quantification of average pixel 
intensity of Amot expression in normal breast tissues vs cancerous breast 
tissues (A), tumors originating from the mammary duct vs the mammary 
lobules (B) by Zen Axiovision Image Processing Software. Levels of Amot 
were normalized to nuclei count. Normal breast tissues: N=10, cancerous 
breast tissues: N=24, ductal carcinoma tissue: N=15, lobular carcinoma 
tissue: N=5. SEM. *p ≤ 0.05. 
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Figure 4-2. Comparison of 
Amot protein expression 
between normal breast 
tissues, and grades I-III 
breast tumor tissues. A. 
Immunofluorescent staining of 
Total Amot (in red). Beta-
catenin (green) marks 
polarized epithelial tissue and 
Hoescht stain (blue) marks cell 
nuclei. B. Quantification of 
average pixel intensity of Amot 
expression in A by Zen 
Axiovision Image Processing 
Software. Levels of Amot were 
normalized to nuclei count. 
Normal breast tissue: N=10. 
Grade I breast tumor tissue: 
N= 5. Grade II breast tumor 
tissue: N=11. Grade III breast 
tumor tissue: N=13. SEM. P 
<0.05. 
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Figure 4-3. Comparison of 
Amot protein expression 
between normal breast 
tissues, and ER negative and 
positive breast tumor 
tissues. A. Immunofluorescent 
staining of Total Amot (in red). 
Beta-catenin (green) marks 
polarized epithelial tissue and 
Hoescht (blue) marks cell 
nuclei. B. Quantification of 
average pixel intensity of Amot 
expression in A. by Zen 
Axiovision Image Processing 
Software. Levels of Amot were 
normalized to nuclei 
count.Normal breast tissue: 
N=10. ER - breast tumor 
tissue: N= 4 ER + breast tumor 
tissue: N=20. SEM. *p <0.05. 
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Figure 4-4. Comparison of 
Amot protein expression 
between normal breast 
tissues, and PR negative and 
positive breast tumor tissues. 
A. Immunofluorescent staining 
of Total Amot (in red). Beta-
catenin (green) marks polarized 
epithelial tissue and Hoescht 
(blue) marks cell nuclei. B. 
Quantification of average pixel 
intensity of Amot expression in 
A. by Zen Axiovision Image 
Processing Software. Levels of 
Amot were normalized to nuclei 
count. Normal breast tissue: 
N=10. PR - breast tumor tissue: 
N= 7 PR + breast tumor tissue: 
N=17. SEM. *p ≤ 0.05 
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Figure 4-5. High Amot expression does not correlate 
with node-positive breast tumors than with node-
negative breast tumors. Quantification of average 
pixel intensity of Amot expression in normal breast 
tissues vs. node negative and node positive breast 
tumors by Zen Axiovision Image Processing Software. 
Levels of Amot were normalized to nuclei count. Normal 
breast tissue: N=10. Node negative breast tumor tissue: 
N= 17. Node positive breast tumor tissue: N=7. SEM. *p 
≤ 0.05 
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Figure 4-6. Comparison 
of Amot protein 
expression between 
non-metastatic / non-
recurrent breast tumor 
tissues, and pre-
metastatic breast tumor 
tissues. A. Immuno-
fluorescent staining of 
Total Amot (in red). Beta-
catenin (green) marks 
polarized epithelial tissue 
and Hoescht (blue) marks 
cell nuclei. B. 
Quantification of average 
pixel intensity of Amot 
expression in A. by Zen 
Axiovision Image 
Processing Software. 
Levels of Amot were 
normalized to nuclei 
count. Normal breast 
tissue: N=10. Non-
metastatic / non-recurrent 
breast tumor tissue: N= 
18. Metastatic breast 
tumor tissue N=3. SEM. 
*p ≤ 0.05. 
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Figure 4-7. Comparison of 
Amot protein expression 
between non-recurrent breast 
tumor tissues and pre-locally 
recurring breast tumor tissue. 
A. Immunofluorescent staining of 
Total Amot (in red). Beta-catenin 
(green) marks polarized 
epithelial tissue and Hoescht 
(blue) marks cell nuclei. B. 
Quantification of average pixel 
intensity of Amot expression in 
A. by Zen Axiovision Image 
Processing Software. Levels of 
Amot were normalized to nuclei 
count. Normal breast tissue: 
N=10. Non-metastatic / non-
recurrent breast tumor tissue: 
N=18. Recurrent breast tumor 
N=3. SEM. *p ≤ 0.05. 
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recurrence also related positively to Amot protein levels, in which recurrent 
tumors exhibit a greater than 4-fold increase in Amot (Fig 4-7A: B). Jiang et al. 
found no difference in transcript levels between recurrent and non-recurrent 
tissues. Interestingly, only one of the three metastatic patients and one of three 
recurrent patients was diagnosed as node-positive, a factor clinically classified as 
a major predictor of tumor aggressiveness. This may implicate the presence of 
excess Amot protein levels as an additional predictor of aggressiveness in breast 
tumors. 
 To further develop this theory, we sought to understand the role of Amot 
as a potential driver of a transition from DCIS to IDC. Although non-obligate, 
DCIS as a precursor to IDC occurs in nearly 40 % of cases [7]. The comparison 
of representative samples from these cases, along with the remaining 60% of 
IDC cases, provide a solid model for studying the significance of a protein in 
driving a DCIS to IDC transition. These tumors provided us the opportunity to 
investigate differences in Amot expression in invasive tumors with or without a 
predominant presence of DCIS lesions. IDC tumors with a high presence of DCIS 
lesions are undergoing multiple DCIS to IDC transitional events, whereas IDC 
tumors with the absence of DCIS are less likely to have undergone transition, 
and rather the invasive disease developed de novo [161,162]. IDC tumors with 
DCIS revealed a 4-fold elevation of Amot over those tumors lacking DCIS 
lesions, indicating the strong correlation of amplified Amot in tumors that have 
undergone DCIS to IDC transitions (Fig 4-8). This is the first study to discover 
increased Amot levels in DCIS to IDC transitions.  
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 The expression level of Amot protein is indeed a key piece of evidence to 
help us understand its role in DCIS to IDC transitions. However, the ability to 
examine the dynamic localization and patterning of the Amot staining within the 
tissue structure and the cells as it related to β-Catenin is a major advantage of 
tissue imaging as opposed to IHC and immunoblot analysis. It is crucial to 
investigate Amot with respect to organ and subcellular localization as it compares 
to the clinical characteristics we have analyzed in this cohort. To accomplish this, 
we analyzed the localization of Amot expression in subcellular compartments 
across all of the samples.  
We identified the presence of Amot in three unique manners within the 
tumor tissue: junctional, punctae, and nuclear / perinuclear (Fig 4-9A). The 
presence of Amot at apical junctions was a staining pattern most similar to that of 
normal ductal structures. This localization indicates a more polarized and growth- 
arrested phenotype, where unphosphorylated Amot 130 sequesters YAP1 at 
polarity protein complexes associated with tight and adherens junctions 
[138,163]. We pooled all of the tissues that exhibited Amot junctional staining and 
found them all to possess predominant DCIS lesions. The average tumor grade 
of these samples was 1.75 +/- 0.8. In these, we observed that Amot is apically 
localized in the highly polarized cells, identifiable by the highly organized pattern 
of beta-catenin staining. However, the cells that are appearing to establish 
regions of micro-invasion tend to possess an altered Amot localization and 
pattern; here, a more punctate aggregation of Amot staining was observed.   
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Figure 4-8. Amot protein levels are more greatly 
elevated in IDC breast tumors with predominant 
presence of DCIS than in IDC breast tumors that lack 
the presence of DCIS. The quantification of average 
pixel intensity of Amot protein expression in normal 
breast tissues vs IDC tumors without presence of DCIS 
and IDC with presence of DCIS by Zen Axiovision Image 
Processing Software. Levels of Amot were normalized to 
nuclei count. Normal breast tissue: N=10. IDC (DCIS - ) 
breast tumor tissue: N= 5. IDC (DCIS + ) breast tumor 
tissue: N=5. SEM. *p ≤ 0.05. 
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Figure 4-9. The pattern of Amot staining and localization is variable in 
tumor tissues verses normal breast tissue. A. Dual immunofluorescence 
staining of total Amot and polarized epithelial marker β-Catenin displays the 
presence of Amot in different locations including at apical junctions, in 
aggregate punctae, and in nuclear and paranuclear compartments. B. The 
tumor grades of the tissues exhibiting the presence of Amot in these different 
subcellular compartment were compared. Tumors with: junctional Amot (N=4), 
Amot in punctae (N=10), and nuclear/paranuclear Amot (N=5). SEM. ANOVA. 
*p≤ 0.05. 
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The presence of Total Amot at juxta nuclear punctae has been proposed 
to mark the association of Amot p80 to the lipid raft-enriched membranes of juxta 
nuclear recycling endosomes [166]. In cells exhibiting a pro-migratory phenotype, 
it is on these endosomes by which Amot 80 co-localizes with pro-migratory 
protein functioning to traffic toward the leading migratory edge of the plasma 
membrane [164]. This is consistent with the patterning of exogenous Amot 80 
staining in fixed cells (data not shown), where the signal occurs predominantly in 
large, dense, aggregates near the nucleus. Sixty percent of the patients with 
tumors we found exhibiting this pattern of Amot staining possessed predominant 
DCIS lesions and thirty percent experienced a metastatic or recurring event. The 
average tumor grade of the tumors displaying punctal Amot staining was found to 
be 2.2 +/- 0.6.  
Additionally, we saw a more diffuse staining of Amot occurring in and 
around the nucleus. Reports have surfaced previously implicating the nuclear 
translocation of the Amot130-YAP1 complex, and even go so far as to 
demonstrate the ability of Amot 130 to function as a transcriptional co-activator 
alongside its binding partner YAP1 [139,165]. We found five samples in our 
cohort that demonstrate Amot nuclear and/or para-nuclear staining. Still, there is 
much more to understand about how the presence of Amot in the nucleus alters 
its governance of YAP1. These tissues possessed an average tumor grade of 1.8 
+/- 0.7, and sixty percent of these tissues were diagnosed as IDC that lacked the 
presence of DCIS lesions. In comparing all of these groups of tumors, we found 
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no significant difference in tumor grade with respect to the distinct localization 
and patterning of Amot (Fig 4-10B).       
A limitation of this study was that we could not report a correlation with 
regard to Her2 status, as every tissue we were able to analyze was Her2 
negative. A recent study, Barutello et al. 2015, examined female Her2+ mice 
which were born and fed from mothers that were injected with the anti-angiogenic 
vaccine against Amot, first reported by Holmgren et al. 2006. High levels of anti-
Amot antibodies were present in the sera of these mice and these levels 
correlated with significant delays in Her2+ tumor growth [166,167]. Analysis of 
more blocks from the TMA, in which more samples may provide more variety 
with regard to Her2 status, would allow for this correlation to be made in the 
future.  
Contrasting with Jiang et al. published, we found that Amot protein 
expression was indeed high in recurrent tumor tissues versus non-recurrent 
tumor tissues. We also found no significant difference in Amot levels between 
tumors derived from the mammary duct versus the mammary lobule, nor did we 
observe a difference in levels between node positive and node negative tumors. 
Conclusively, we have supported the mRNA evidence for elevated Amot levels in 
breast cancers with respect to several clinical and histological features. First, we 
found that Amot protein expression was elevated in breast cancer over normal 
breast tissues. We also found that Amot levels were higher in metastatic versus 
non-metastatic breast tumor tissues [130]. 
  
80 
Our further analysis that expanded the study by Jiang et al. sought to 
investigate the changes in Amot levels in tumors undergoing DCIS to IDC 
transitions, verses those tumors that arose de novo. We found a significant 
increase in Amot protein expression in the transitioning tumors, implicating Amot 
as a potential player in this process. All of these transitioning tumors possessed 
an Amot staining pattern associated with the promotion of a migratory phenotype.  
Ultimately, we are interested in continuing this work in additional blocks in 
the tumor microarray. The ability to investigate how Amot protein expression and 
staining pattern associate with patient survival and Her2 status would further 
complement the initial work we have completed, and possibly add support to the 
potential for the anti-Amot vaccine to move into clinical trials.    
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CHAPTER 5: A SINGLE PROMOTER GOVERNS THE TRANSCRIPTIONAL 
ACTIVATION OF THE LONG (130 KDA) ISOFORM AND THE SHORT (80 
KDA) ISOFORM OF ANGIOMOTIN 
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5.1. Introduction 
The Angiomotin proteins are highly conserved and generally function as 
scaffolding proteins within the HIPPO growth control pathway in the breast and in 
other tissues [168]. First published in 2001 by Troyanovsky et al., Angiomotin 
was initially identified as an 80 kDa protein that binds angiostatin and that 
induces the migration of endothelial cells [169]. To date, 123 studies discussing 
Angiomotin have been published. Angiomotin was also found to be directly 
involved in chemotaxis [169,170]. It was subsequently appreciated that the 
AMOT gene yields two distinct isoforms. Amot p130 is a 130 kDa protein 
comprised of 1084 amino acids coded for by ten translated exons. Amot p80 is 
an 80 kDa protein comprised of 675 amino acids coded for by nine translated 
exons. Because only exon 1 of the 10 translated exons that code for Amot 130 is 
not shared with Amot 80, it was reported by Bratt et al. 2005 that these two 
isoforms are generated through alternative splicing [129]. Literature discussing 
the existence of these two isoforms did not appear until 2005, and the seventeen 
studies published since then regarding their localizations and functions are quite 
controversial. Amot p130 was first recognized in endothelial cells where it was 
found to localize at tight junctions and on actin fibers [137]. Amot p80 was found 
to colocalize with Amot 130 at the tight junctions, but not on actin fibers.  Amot 
p80 was also found to be present at lamellipodia of migrating cells, suggesting its 
role in driving cell movement and migration [129]. Since then, both isoforms have 
also been found to exist perinuclearly [164], as well as intranuclearly [139]. Most 
reports also find that Amot 80 acts as a dominant negative regulator of Amot 130. 
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This was initially found to redirect Amot and its associated apical polarity protein 
complexes to juxta nuclear endosomes resulting in a loss of tight junction 
integrity [164]. Unpublished work from our lab finds that Amot 80 also redirects 
the Amot 130/YAP1 complex away from cell junctions to juxta nuclear 
endosomes. While Amot 130 was initially reported to drive epithelial apical 
polarity and to inhibit cell growth and migration, it is now appreciated that it 
functions in this manner only in the presence of low levels of Amot 80 and when 
phosphorylated by LATS 1/2 [136]; Ranahan et al. unpublished. This study seeks 
to identify the manner by which the transcription of Amot 130 and Amot 80 are 
controlled. This, in turn, may provide insights into how such expression is 
upregulated to promote cancer initiation, promotion, and progression.  
 
5.2 Methods and Materials 
Genetic inactivation of Amot via CRISPR.  
Complementary guide RNAs of 18 base pairs were designed to target 
specific regions of the Amot genome upstream of pan sequences. Annealed 
guide RNA sequences were cloned into a clustered regularly interspaced short 
palindromic repeats (CRISPR) lenti-viral plasmid (Sigma). HEK 293T cells were 
stably infected with the Amot transcription start site (TSS) CRISPR target 
construct or the empty CRISPR control. Cells then underwent puromycin 
selection for a duration of two weeks; clones were isolated and passaged prior to 
harvest. 
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5’ Rapid Amplification of cDNA Ends (5’ RACE) of human cDNA.  
Total RNA was harvested from HEK 293T and MDA-MB-468 cells using 
Trysol-chloroform extraction. The 5’ RNA ligase-mediated rapid amplification of 
cDNA (RLM-RACE) reactions were performed using the First Choice RLM-RACE 
protocol (Ambion).  Complementary DNA (cDNA) was synthesized from the 
linker-ligated RNA using reverse transcriptase and random octamers. PCR 
amplification of the linker-ligated cDNA was performed using the 5’ RLM-RACE 
Kit Outer Linker Primer and 3’ Primers designed to specifically target each 
individual Amot isoform. 
 
Synthesis of the Angiomotin Promoter.  
The Amot Promoter was synthesized by GenScript DNA Synthesis 
Services and corresponds to GrCh 38 position 112840700 to 112842172 which 
includes the most 5’ transcriptional start site (experimentally discovered) and 
flanking Kpn1 and HindIII restriction sites. Kpn1 and HindIII sites were utilized in 
cloning the Amot Promoter insert into a pGL3 Basic Luciferase Vector backbone. 
Naturally occurring restriction sites within the sequence include: Two Apa1 sites, 
one EcoR1 site, one Mlu1 site, and one Sac1 site. Diagnostic digestions for all 
the sites demonstrated successful cutting of the Mlu1 site. The Mlu1 site occurs 
between the two RNA polymerase 2A binding regions identified by ENCODE in 
the Amot promoter. This Mlu1 site was then utilized to successfully replace the 
wild type promoter sequence with another synthesized sequence in which all 5 
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occurring SP1 transcription factor binding sites were mutated construct to 
determine the regulatory region most important for AMOT gene transcription  
 
Genomic Bioinformatics 
 The following databases were employed to build the various diagrams 
depicting the genomic structure of the AMOT gene: National Center for 
Biotechnology Information (NCBI): Expressed Sequence Tags (EST), Gene, and 
Basic Local Alignment Search Tool (BLAST), Ensembl Genome Browser, 
University of California Santa Cruz (UCSC): Genome Browser, GeneBlat, and 
Encyclopedia of DNA Elements (ENCODE). Information provided by these 
databases was used to build comprehensive diagrams, align PCR sequencing 
data, investigate potential splicing patterns, and identify key promoter elements 
and potential regulatory factors.      
 
5.3. Results 
The location of the Amot promoter has been proposed to lie either 
immediately upstream of the first exon of Amot 130 [128] or in an unidentified 
region almost 20,000 base pairs upstream of this location. Upon investigating the 
expressed sequence tags (ESTs) that shared sequences with exons that encode 
Amot, multiple non-coding exonic sequences were found to occur upstream of 
the known Amot p130 coding exons. Further, these exons were joined 
alternatively to lack the first coding exon but contain the second coding exon so 
that they likely also contribute to the expression of Amot p80. Based on the 
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genomic structure of the AMOT gene, there is also evidence to potentially 
support the existence of two distinguishable promoters (Fig 5-1). We set out to 
identify the transcriptional start site(s) for the AMOT gene and then use this to 
define the location(s) of the Amot promoter(s).  
For this purpose, a diagram of the genomic architecture of the AMOT 
gene was compiled from a variety of genomic databases. The consensus was 
that the AMOT gene has a total of thirteen exons, three of which occur in the 5’ 
leader region upstream of both Amot 130 and Amot 80 translational start sites 
(Fig 5-1). The analysis of the expressed sequence tags (ESTs) aligning with 
Amot p130 verses Amot p80 yielded overwhelming evidence to support a single 
promoter upstream of exon 1 between ChrX(-) 112842172-112840700 (Fig 5-1; 
Fig 5-2). However, an additional region of active chromatin to which RNA 
Polymerase 2A and transcription factors bind occurring between ChrX(-) 
112835473-112832385 indicated a potential second promoter just upstream of 
the start of exon 2 (Fig 5-1). Determining the location of the promoter element(s) 
that regulate the activation of the Amot isoforms required us to define the 
transcriptional start site(s) for Amot 130 and Amot 80. To accomplish this, we first 
had to characterize the 5’ regulatory region of the AMOT gene. According to our 
investigation of Amot across multiple nucleotide databases, including NCBI, 
Ensembl, and UCSC genome browser, it appears that one transcriptional start 
site is recognized as the sole transcriptional start site (TSS) controlling the 
transcriptional activation of both Amot isoforms. Interestingly, the region 
upstream if this location lacks both common promoter sequence motifs TATA or 
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CCAAT, but analysis of UCSC Encyclopedia of DNA Elements (ENCODE) 
database indicates a concentrated region of transcriptional factor and RNA 
polymerase binding, as well as active open chromatin at a location further 
upstream of the indicated TSS. This led us to experimentally validate the actual 
TSS site(s) for Angiomotin using  the 5’ Rapid Amplification of cDNA Ends (5’ 
RACE) method [171].  
In order to ensure that only true TSS(s) would be identified from the 5’ 
RACE experiments, we used cDNA libraries prepared from HEK 293T and MDA-
MB-468 cells in which the 5’ mRNA cap of the extracted RNA was removed and 
replaced with a 20 base pair DNA linker. The subsequent polymerase chain 
reaction (PCR) amplification utilized the 5’ primer sequence that anneals to the 
linker DNA and a 3’ primer sequences that complement either the Amot 130 
(exon 4) or the Amot 80 (exon 2) specific-noncoding exons. The PCR 
amplification products were then cloned and the consequent libraries were 
exhaustively sequenced. This sequencing revealed a consensus from both the 
293T and MDA-MB-468 cell lines for three closely spaced transcription start sites 
before exon 1 (Fig 5-3). This supports the premise that a single promoter controls 
the expression of both Amot 80 and Amot 130 transcripts.  
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Figure 5-1. A Schematic of the potential promoter regions of the Amot 
gene. The compiled illustration of the location of H3K27Ac and H3K4me3 active 
chromatin histone mark signals, DNAse hypersensitivity, binding of RNA 
polymerase 2A and transcription with respect to the Exon1 and Exon 2 positions 
depicts the potential regions of transcriptional start sites along the Amot gene. 
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Figure 5-2. The analysis of Amot cDNAs highlight the potential for 
alternative splicing of the Amot gene. A. Expressed Sequence Tags (ESTs) 
from the UCSC genome browser revealed the frequencies of various Amot 
exon-exon junction combinations. The exon-exon junction between 1-2 anneals 
to both isoforms. The exon-exon junction between 2-5 anneals to Amot 80, and 
excludes exon 3 and 4. The exon-exon junction between 2-3-4 and 4-5 anneals 
to Amot 130. B. Quantitative RT-PCR was performed amplifying the various 
exon-exon junction combinations. 
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Figure 5-3. A single transcription start site and promoter regulate the 
expression of Amot 130 and Amot 80. A. 1 % Gel imaging of PCR products 
resulting from 5’ RNA Amplification of cDNA Ends (RACE) experiments 
performed in MDA-MB-468 and HEK 293T cells. B. cDNAs resulting from 5’ 
RACE experiments in both HEK 293T and MDA-MB-468 cells were synthesized 
and PCR was ran using primers that anneal to either the Amot 80 specific Exon 
2 or Amot 130 specific Exon 4. PCR product sequencing identified three novel 
transcription start sites for the Amot gene. 
A 
B 
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More definitive confirmation that the transcription of both Amot isoforms 
were regulated by a single promoter was provided by the dramatic loss of protein 
expression of both Amot p130 and Amot p80 in cells in which a CRISPR/CAS9 
plasmid had been stably introduced that contained a small guide RNA (sgRNA) 
targeting the most 5’ TSSs in exon 1 (Fig 5-4A-B). Disruption of this site was 
validated by genomic sequencing (Fig 5-4C-D). Taken together, both Amot 
isoforms are found to be expressed from a single promoter upstream of exon 1. 
While this data is consistent with the recent report of a promoter lying upstream 
of exon 1, this study did not define a TSS nor did they show how this fairly 
undefined region controlled Amot 80 verses Amot 130 expression [172].  
Although the results from the 5’ RACE indicated multiple TSS locations along the 
AMOT gene, these sites appear not to be mutually exclusive.  
In order to identify which transcripts are expressed from TSS1, reverse 
transcriptase PCR (RT-PCR) was performed using primers designed to anneal to 
the exons unique to each isoform and amplify various exonic combinations along 
the AMOT gene (Fig 5-2B; 5-5B). The amplification of exons 2 to 5 produced a 
PCR product that was shorter that the product resulting from the amplification of 
exons 2-4 and 3-5. This finding further supports the theory that the both Amot 
isoforms are made from the alternative pre-mRNA splicing in which exons 3 and 
4 are removed from the transcript coding for Amot 80, and are not the result from 
the activation of multiple Amot Promoters (Fig 5-6). This is reminiscent of 
AmotL1, which produces similar long and short isoforms from alternative splicing 
[134].  
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Figure 5-4. Genetic inactivation of the most 5’ transcription start site 
eliminates mRNA and protein expression of both Amot isoforms. A. HEK 
293T cells infected with lentiviral plasmids inserted with CRISPR guide RNAs 
targeting regions of the Amot gene near the TSSs found experimentally with the 
5’ RACE were immunoblotted and probed for Amot and GAPDH. B.  Total Amot 
mRNA levels were detected by qRT-PCR of HEK 293T cells infected with Amot 
CRISPR 1, puromycin selected clone 1A. N=3, S.D., Student’s T-test, *p < 0.01. 
C. 1 % Gel imaging of PCR products from the amplification of genomic DNA 
from CRISPR Control or Amot CRISPR 1A cells with primers flanking the 18 
base pair guide RNA sequence. D. The compiled map of the location of the 
Amot CRISPR guide RNA relative to the experimentally verified TSS 1 and 2. 
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 The identification of Amot isoform specific untranslated exons provides the 
opportunity to design novel primer sets that distinguish Amot 130 and Amot 80 
transcript levels. Therefore, we designed primer sets for quantitative RT-PCR via 
SYBR green, which require amplicon lengths between 70 and 150 base pairs, 
and melting temperatures between 59 and 61 C. For the specific detection of 
Amot 130, we designed a primer set to amplify the exon junction between exons 
3 and 4. For the detection of Amot 80, we designed a primer set to amplify the 
exon junction between exons 2 and 5. Total Amot detection employed a primer 
set that detects in exon 9. To verify these primer sets, we exploited an 
observation that our lab has made with respect to the differential silencing of the 
Amot isoforms by the Amot shRNA construct. This construct demonstrated that 
Total Amot knockdown by shRNA resulted in the silencing of Amot 130 at 48 hrs 
post infection, and Amot 80 72 hours post infection (Fig 5-7A).  This differential 
knockdown created a perfect opportunity to validate these Amot isoform-specific 
primer sets via RT-PCR (Fig 5-7B).  
The characterization of the Amot promoter guided our development of a 
luciferase-based reporter construct (pGL3.1 basic) containing 1500 base pairs 
upstream of exon 1. The exact length of this putative promoter was predicted 
based on a comprehensive analysis including the location of the active chromatin 
regions, DNase I hypersensitivity sites (DHSs), and the concentration of 
transcription factor binding near the RACE validated TSS. Active chromatin was 
delineated by histone H3K27Ac and H3K4me3 marks which mark active regions  
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Figure 5-6. The Amot isoforms display alternative exon junctions. 
Compiled illustration of the unique exon splicing of the 5’ leader region yielding 
two Amot isoforms generated from a single transcription start site.  
 
  
96 
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Figure 5-7. The Amot isoform specific exons in the 5’ leader region 
provide the opportunity to design primer sets that can distinguish the 
transcriptional activation of Amot 80 verses Amot 130. A. MDA-MB-468 
cells infected with Amot shRNA lentivirus were collected after 24 hours to 
enrich for cells specifically silenced for Amot 130, or after 72 hours to enrich 
for cells that exhibited the knockdown of both isoforms when compared to 
control. B. The Amot isoform-specific primer sets were used to amplify cDNA 
from the cells in A. The Amot 130 primer set amplified across the exon-exon 
junction between exons 3-4, the Amot 80 primer set amplified between exons 
2-5, and the Total Amot primer set amplified the region in exon 9. N=3. SD. P 
≤ 0.05. 
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with high DNA accessibility in the ENCODE database. DNase I hypersensitivity is 
a direct measure of regions of highly active DNA regions, as euchromatic DNA is 
far more sensitive to cleavage than heterochromatic DNA by DNase enzymes. 
The relative darkness of the band, and its corresponding score between 0 and 
1000, is related to the signal strength reported from the investigators and is 
normalized according to UCSC regCluster, a universal scoring standard 
regulated by UCSC. A score greater than 100 is considered significant (Fig 5-1). 
Transcription factor and polymerase binding was found in the compilation of 
chromatin immunoprecipitation sequencing (Chip-Seq) data from the ENCODE 
project, which provides the location of the binding region(s) and the specific DNA 
consensus motif site(s) of all of the transcription factor and polymerase proteins 
that occupy a promoter. Additionally, ENCODE provides the cluster score of each 
transcription factor, which is a number between 1-1000 that is relative to the 
signal strength reported from the investigators and normalized by the UCSC 
transcription factor binding site (TFBS) cluster standard. A cluster score greater 
than 300 is considered to be significant (Fig 5-8A) [96].   
The full length Amot promoter reporter construct was then transfected into 
cells alongside a renilla transfection control vector. Promoter activity determined 
by the measurement of ratio of luciferase expression to renilla expression via 
luminometer detection. The cells were subjected to treatment with IL-6, which 
exhibited increased promoter activity. In addition, a co-treatment with IL-6 and a 
STAT3 inhibitor (C188-9), which functions to compete for STAT3 SH2 domain  
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Figure 5-8. A schematic of the Amot promoter and the subsequent serial 
deletion reporter constructs and the transcription factors found to bind 
the region. A map depicting ENCODE transcription factor binding in the 
region 1450 base pairs upstream of TSS1. Transription factors are plotted and 
color coded according to their cluster scores. B. The full Amot promoter along 
with four serial deletion constructs are depicted which gradually eliminate 
unique regions of transcription factor and RNA Pol2A binding of the Amot 
promoter. These constructs were all inserted into the pGL3 Basic Luciferase 
plasmid. 
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binding, blocked the amplification of Amot promoter activity by IL-6. Both of these 
results were in agreement with endogenous immunoblot data (shown in Fig 6-6; 
Fig 6-3D). 
A series of deletion constructs that were shortened at the ends farthest 
from exon 1 were then cloned into the pGL3 basic vector (Fig 5-8B). These were 
designed for the key transcription factors necessary for Amot promoter activity. 
The full length reporter and the four deletion reporters were transfected into cells 
and they were measured for luciferase activity. This analysis found that the 
region between -563 and -1473 base pairs of the reporter is critical for basal 
Amot promoter activity, indicating the high significance of the transcription factor 
and polymerase binding that occupies that region. In contrast, it appears that the 
transcription factors that bind in the region between -1 and -563 are fully 
sufficient in activating the Amot promoter (Fig 5-9). This data aided in narrowing 
down the list of transcription factors that are key in the transcriptional regulation 
of the Amot isoforms.    
 
5.4 Discussion 
 In this study, we sough to determine the regulatory mechanism governing 
the transcription of the unique isoforms of Amot: Amot 130 and Amot 80. The 
correlation of Total AMOT mRNA and protein levels with highly aggressive breast 
tumors, along with the numerous studies that debate the specific roles and 
functions of the Amot isoforms in cellular programs relevant to breast cancer 
indicate a strong need for a greater understanding of how these unique isoforms 
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are made at the transcriptional level [130,131]. Not only did we identify the single 
transcription start site of the AMOT gene, indicating that both isoforms are indeed 
controlled by a single promoter (Fig 5-3; 5-4), we have determined that these 
unique gene products are generated through alternative splicing (Fig 5-2; 5-5). 
Our data strongly demonstrated that the AMOT gene is spliced in the following 
way: Exon 1-2 splices directly into exon 5 for the production of the dominant 
negative Amot 80 isoform. The excision of exon 4 from Amot 80 is a key event in 
controlling the translation to favor Amot 80 expression, as the start methionine 
responsible for the translation of the Amot 130 isoform is present in exon 4. 
Therefore, Amot 130 undergoes no splicing; its mRNA contains all 12 exons (Fig 
5-6). Our appreciation of the unique exons comprising the Amot isoforms led us 
to create Amot isoform specific qRT-PCR primer sets that will allow us to 
distinguish Amot 130 and Amot 80 transcript levels (Fig 5-7B). The generation of 
this reagent may be a key method in determining what is driving the alternative 
splicing to favor one isoform over the other, as well as understanding how the 
ratio of Amot 130 to Amot 80 transcript and protein levels contribute to breast 
cancer. Because Total AMOT mRNA levels have been shown to correlate 
strongly with reduced survival of breast cancer patients [130], the detection of the 
Amot isoform transcript ratio could become an even more specific diagnostic tool 
as we discover more about the distinct roles of the isoforms in breast cancer. 
Additionally, our work identified and fully mapped out the key regulatory region 
for the AMOT gene (Fig 5-8A), and we have begun to narrow down the identities 
of several transcription factors that appear to be greatly responsible for Amot 
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promoter activity (Fig 5-8; 5-9). The results from this study have provided a 
number of insights to determine what controls the expression of the Amot 
isoforms.  
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CHAPTER 6: SPECIFICITY PROTEIN 1 INDUCES THE EXPRESSION OF 
ANGIOMOTIN IN RESPONSE TO IL-6/STAT3 ACTIVATION TO MEDIATE 
YAP1 DEPENDENT GROWTH OF BREAST CANCER CELLS 
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6.1. Introduction 
 An inflammatory tumor microenvironment secretes a variety of cytokine 
effectors. Some of these include Interferon gamma IFNγ, tumor necrosis factor 
alpha (TNFα), and interleukin 6 (IL-6). All three of these cytokines correlate with 
the 50 % of DCIS cases with inflammatory microenvironments and have been 
reported to promote the progression of breast cancer [38,121,173-176]. IL-6 and 
IFNγ have both been shown to innervate the promotion of growth and survival 
through the STAT family members, the activation of which has been shown to 
foster the nuclear accumulation of YAP1 [121,177]. The mechanism of signaling 
between the activation of STAT3 and the translocation of YAP1 has not been 
investigated. As we have discussed the significance of the Amot isoforms in the 
control of YAP1 nuclear translocation, we sought to answer whether Amot is 
required for STAT3 induced YAP1 activation.      
 
6.2 Methods and Materials 
 
3-Dimensional Matrigel© Culture  
Matrigel© was thawed from -20 oC on ice for a duration of 4 hours.  
Matrigel© was then plated and incubated at 37 oC for a duration of 5 minutes. 
Approximately 250,000 cells were seeded into the Matrigel© and covered in 
media until the Matrigel© was submerged. Cells were cultured for a duration of 
four days, and media was changed once every 2 days. Cultures were then 
harvested for RNA and/or protein for analysis. 
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Interleukin (IL-6) Treatment Assays  
Interleukin 6 (IL-6) (PeproTech) was diluted to 1 μg/mL stock in 0.2% 
bovine serum albumin (BSA) / water and stored at -80 oC until use. Per 
PeproTech’s records, this lot of IL-6 scored a 50% active concentration (AC50) of 
0.1 ng/mL for a duration of 64 hours. For multi-day assays, IL-6 media was 
changed once every 48 hours to ensure consistent molecular activity. IL-6 was 
diluted to the following concentrations in Optimem © for various assays: 0.03 
ng/mL, 0.1 ng/mL, 0.3 ng/mL, 1.0 ng/mL, 3.0 ng/mL, 10 ng/mL, and 100 ng/mL. 
Vehicle control media was prepared with BSA to mimic the highest concentration 
of IL-6 being tested. For 3-dimensional Matrigel© assays, IL-6 and BSA Vehicle 
were diluted in Complete DMEM for MCF7 and MDA-MB-468 cells, or Complete 
Matrigel© Assay Medium (MCF10A media supplemented with 5% Matrigel©) for 
pre-tumorigenic MCF10A cells. 
 
Verteporfin Treatment Assays 
Verteporfin was diluted to 1M in a DMSO stock and stored at -80 oC until 
use. It was diluted to a concentration of 1 μM for cell based assays. Control cells 
were treated with DMSO. Verteporfin and control media was changed once every 
48 hours to ensure high activity. Detection of CTGF levels via qRT-PCR 
confirmed reduced YAP1-TEAD transcriptional targets in response to Verteporfin.  
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Mithramycin Treatment Assays 
 Mithramycin was obtained from Dr. Mircea Ivan’s laboratory (IUSM) at a 
20M DMSO stock. It was diluted to a concentration of 20 mM for cell based 
assays. Control cells were treated with DMSO. Mithramycin and control media 
was changed once every 24 hours to ensure high activity. Immunoblot confirmed 
reduced Sp1 levels in response to Mithramycin. 
 
C188-9 Treatment Assays 
 C188-9 STAT3 inhibitor was obtained from Dr. Teresa Zimmers laboratory 
(IUSM) and was diluted to a stock concentration of 30 mM. It was diluted to a 
concentration of 30 μM for cell based assays. Control cells were treated with 
DMSO. C188-9 and control media was changed once every 24 hours to ensure 
high activity. Immunoblot confirmed reduced STAT3 levels in response to C188-
9. 
  
Tissue Digestion and Harvest 
 Mouse myocardial STAT3 WT and KO tissues were obtained from Dr. Xin-
Yuan Fu’s laboratory (IUSM) and post hepatectic and control mouse muscle 
tissues were obtained from Dr. Teresa Zimmer’s laboratory. In both instances, 
tissue samples were transferred back to the Wells’ lab in liquid nitrogen. The 
frozen tissue was ground with a cold mortar and pestle and transferred to round 
bottom tubes for sonication and homogenization in 2 mLs of Tri-Reagent. RNA 
extraction proceeded as described in Chapter 2 of this dissertation.   
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Stereo Imaging 
 Stereo imaging was conducted on a Nikon SMz 1500 Model C-BD115 
120V, 50-60 Hz under 10X or magnifications.  
 
Quantification of Stereo Imaging 
 ImageJ software was used to quantify the cross-sectional area (in pixels2) 
of 3-D mammary acinar colonies cultured in Matrigel©. 
 
6.3 Results 
Our initial investigation into the potential convergence of inflammation with 
the dysregulation of HIPPO signaling examined the impacts of various cytokines 
that are commonly found in breast cancers on the Amot promoter activity, as well 
as YAP1 and TAZ protein levels in MDA-MB-468 cells. Interleukin 6, Tumor 
Necrosis Factor-α, and Interferon-γ are three commonly secreted cytokines found 
to correlate in aggressive breast cancers. We found that the cytokine that 
induced the greatest impact on both Amot promoter activity and YAP1 and Taz 
protein expression levels was IL-6. IFNγ and TNFα showed no increase in YAP1 
levels and only IFNγ showed an increase in Amot promoter activity (Fig 6-1A; B). 
This IL-6 data is in agreement with the studies showing the requirement of YAP1 
in liver regeneration, a process tightly controlled by IL-6 [118,178,179]. 
Additionally, YAP1 levels were seen to increase dramatically in post hepatectic 
livers, in direct correlation with PSTAT3 levels [180-182]. In collaborative work 
with Dr. Teresa Zimmers, we examined the changes in the levels of YAP1 target  
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Figure 6-1. Of the three most common cytokines found in 
breast cancer, IL-6 induced the greatest elevation of Amot 
promoter activity as well as YAP1 and Taz protein levels. A. 
The full length Amot promoter luciferase construct was transfected 
into HEK 293T cells and treated with 0.5 ng/mL TNFα, IFNγ, IL-6, or 
0.1% BSA/DMSO control for a duration of 20 hours and luciferase 
activity was detected. N=6, S.E., Student’s t-test, *p < 0.01. B. 
MCF10A cells treated with TNFα, IFNγ, IL-6, or 0.1% BSA/DMSO 
control for a duration of 24 hours were harvested for immunoblot 
and probed for YAP1, Taz, and GAPDH loading control. 
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gene CTGF in the cachexic muscle tissue of post hepatectic mice as compared 
to controls. Liver regeneration is widely implicated in driving up serum IL-6 
concentrations, leading to the direct induction of muscle tissue de-differentiation 
rendering muscles cachexic [183]. In the post hepatectic muscle tissue, we saw a 
marked increase in CTGF and TOTAL AMOT transcript levels, correlating with 
the elevated levels of known cachexia marker PAX7, when compared to control 
tissue (Fig 6-2) [184]. This work demonstrated the first connection of pro-
inflammatory signaling to the de-differentiation of tissue and the dysregulation of 
HIPPO signaling to favor the production of CTGF via elevated AMOT levels. We 
thus sought to explore this connection in breast cancer cells.  
In order to determine that the increase of CTGF transcript levels by IL-6 is 
indeed YAP1 dependent, YAP1 nuclear translocation in response to IL-6 was 
detected via fixed-cell immunofluorescent staining of YAP1. Treatment with IL-6 
resulted in a dramatic increase in the presence of YAP1 (shown in green) inside 
the nucleus (stained in blue) (Fig 6-3A). Intra-nuclear YAP1 has been verified to 
correlate with a pro-growth and –survival phenotype, where it functions as a 
transcriptional co-activator of many transcription factors, which, in turn, 
stimulates the expression of genes that foster growth and anti-apoptotic cell 
programming. Ectopic expression of CA-STAT3 resulted in an increase in total 
YAP1 levels and a marginal decrease in the ratio of phosphorylated YAP1 over 
Total YAP1 (Fig 6-3B). The phosphorylated state of YAP1 has been verified to 
remain cytosolic, rendering the coactivating function of nuclear YAP1 inoperable 
[185]. Likewise, we saw no change in the ratio of phosphorylated LATS1 over  
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Figure 6-2. CTGF and Amot mRNA levels correlate with 
positive cachexia marker Pax7 in muscle tissue from post-
hepatectic mice.  Muscle tissue was extracted from mice seven 
days after undergoing partial hepatectamies (PH Day 7) or 
control mice. These tissues were harvested and analyzed for 
measured for CTGF, TOTAL AMOT and muscle cachexia 
marker PAX7,mRNA levels via qRT-PCR. N=4, S.E. Student’s t-
test, *p < 0.005.  
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total LATS1 in the same cells, highlighting that the impact of IL-6 on HIPPO 
signaling is likely innervates another HIPPO protein (Fig 6-3B). Conversely, total 
YAP1 levels were also found to be reduced upon the silencing of STAT3 by 
shRNA (Fig 6-3C). These data were further supported by the data showing that 
CTGF mRNA levels were increased inresponse to treatment with IL-6, and 
decreased in response to the silencing of STAT3 by shRNA (Fig 6-3D;E). Note 
that the elevated CTGF levels also correlated with enhanced growth of normal 
mammary acini induced by IL-6 (Fig 6-3D).   
Taking into account that the impact of IL-6 on YAP1 is not through the 
deactivation of the LATS1 kinase, along with the preliminary data showing the 
enhanced Amot promoter activity and total transcript levels by IL-6, we sought to 
further study the impact of IL-6 on Amot-dependent YAP1 activity. Firstly, we 
investigated whether modulations in the IL-6 pathway produced differential 
effects on the levels of Amot 130 verses Amot 80 transcript levels. The levels of 
AMOT 130, AMOT 80, TOTAL AMOT, and STAT3 transcripts were compared 
between a mouse myocardial STAT3 knockout (KO) and wild type (WT) control 
mouse. While we found that all AMOT transcripts correlated strongly with STAT3 
levels, these data demonstrated no distinguishable difference between the 
effects of IL-6 pathway modulation on AMOT 130 verses AMOT 80 transcript 
levels (Fig 6-4A; B). This implied that alternative splicing of the AMOT gene was 
not affected by the activation or silencing of STAT3, and thus we sought no 
reason to study this further. For all remaining experiments, we decided to focus 
on detecting only the TOTAL AMOT transcript levels. In response to IL-6  
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Figure 6-3. IL-6 drives the nuclear translocation of YAP1, elevates YAP1 
levels and increases the levels of YAP1 target gene CTGF through the 
activation of STAT3, independently of LATS1. A. MCF7 cells were plated 
onto glass coverslips, treated with IL-6, PFA fixed and stained for YAP1 (in 
green) and nuclei (in blue). B-C. MDA-MB-468 cells stably expressing the 
constitutively active form of STAT3, STAT3 shRNA, or control were harvested 
for immunoblot and probed for HIPPO pathway proteins and GAPDH loading 
control. D. MCF10A cells treated with IL-6 and grown in a laminin rich 3D 
Matrigel© environment were imaged and then harvested and measured for 
CTGF and STAT3 mRNA levels via qRT-PCR. N=3. SD. *p ≤ 0.01. E. STAT3 
depleted (shRNA) MDA-MB-468 cells were harvested and measured for 
CTGF and STAT3 mRNA levels via qRT-PCR. N=3. SD. *p ≤ 0.01. 
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Figure 6-4. The Amot isoform-specific transcripts are 
not differentially regulated by IL-6/STAT3 signaling. A-
B. AMOT 80, AMOT 130, TOTAL AMOT, and STAT3 
mRNA were detected in hearts from mice expressing a 
myocardial STAT3 adenoviral knockout genotype and 
compared to wild type (A) or MDA-MB- 468 cells treated 
with 0.1 ng/mL IL-6 for a duration of 24 hours. N=3, S.D., 
Student’s t-test, *p < 0.01. 
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treatment, Total Amot transcript levels correlated strongly with STAT3 transcript 
levels in MDA-MB-468 cells (Fig 6-5A), which are canonically increased in 
response to IL-6 activated signaling. This demonstrates that IL-6 signaling has a 
transcriptional impact on Amot expression. 
Additionally, treatment with increasing concentrations of IL-6 for a duration 
of 24 hrs was found to enhance the protein expression of both Amot 130 and 
Amot 80 in MDA-MB-468s (Fig 6-5B). This increase in Amot protein levels 
occurred only after an IL-6 treatment duration of at least 12 hours and most 
strongly after 24 hrs, indicating an indirect activation (Fig 6-5C). Furthermore, the 
ectopic expression of CA-STAT3 yielded an increase in both Amot isoform 
protein and transcript expression (Fig 6-6A). The silencing of STAT3 via shRNA 
or STAT3 inhibitor (C188-9) resulted in reduced TOTAL AMOT transcript and 
protein levels in MDA-MB-468 cells, even in response to IL-6 treatment (Fig 6-
6C-D). This data supports the requirement of STAT3 for the increase of Total 
Amot resulting from IL-6. Additionally, exogenous expression of a dominant 
negative form of STAT3 (D.N. STAT3) also resulted in a dramatic reduction of 
Amot protein levels (Fig 6-6B). For this reason, the postulation of a potential 
transcriptional effect of IL-6 signaling on Amot expression arose.  
To understand the potential mechanism of Amot transcriptional activation 
in response to IL-6, the promoter of Amot was investigated. Treatment of cells 
transfected with the full length Amot promoter with IL-6 resulted in a greater than 
3-fold activation over cells treated with vehicle control. Treatment with STAT3 
inhibitor C188-9 alone yielded no activation over control, and a combined  
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cells treated with 0.1 ng/mL IL-6 for a duration of 24 hrs were harvested and 
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Figure 6-6. The elevation of Amot transcript and protein levels by IL-6 
requires the activation of STAT3. A. MDA-MB-468 cells stably expressing 
constitutively active STAT3 (CA-STAT3), STAT3 shRNA, or control were 
harvested for immunoblot and probed for Amot, STAT3, and GAPDH loading 
control and measured for CTGF and STAT3 mRNA levels via qRT-PCR. N=3. 
SD. *p ≤ 0.01. B. MDA-MB-468 cells stably expressing the following flag-
tagged forms of STAT3: CA-STAT3, wild type (WT STAT3), dominant negative 
(D.N. STAT3) were harvested for immunoblot and probed for Amot, Flag, and 
GAPDH loading control. C. MDA-MB-468 cells in 2-D culture infected with 
shScramble or shSTAT3 lentivirus and treated with 0.1 ng/mL IL-6 were 
harvested for protein and probed for Total Amot, STAT3, and GAPDH loading 
control. D. MDA-MB-468 cells in 2-D culture treated with 0.1 ng/mL IL-6, 30 uM 
C188-9 STAT3 inhibitor, IL-6 and C188-9, or 0.1% BSA/DMSO control for 24 
hours were harvested for protein and probed for Amot, P(Y705)-STAT3, 
STAT3 and GAPDH loading control.  
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Figure 6-7. IL-6 elevates the Amot promoter activity above 
basal levels through STAT3. The full length Amot promoter 
luciferase construct was transfected into HEK 293T cells and 
treated with 0.5 ng/mL IL-6, 30 uM C188-9 STAT3 inhibitor, IL-6 
and C188-9, or 0.1% BSA/DMSO control for a duration of 20 
hours and luciferase activity was detected. N=9, S.E.M., 
Student’s t-test, *p < 0.01. 
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treatment of IL-6 and C188-9 also yielded no activation (Fig 6-7). These data not  
only indicate the robust ability of IL-6 to activate the Amot promoter, but further 
demonstrate the requirement of active STAT3 to induce this effect. Commonly, 
this  signaling induces transcriptional activation through the binding of phospho-
STAT3 homodimers to promoters [83]. Interestingly, the ENCODE database 
lacked any occurrence of STAT3 in the active chromatin region of the Amot 
promoter that comprises this reporter construct (Fig 6-8A). This demonstrated the 
need to further analyze the transcription factors that do occur in this region and 
their responsiveness to IL-6/STAT3 signaling. To narrow down the search, four 
serial deletions of the reporter construct were transfected into cells treated with 
IL-6 or vehicle control and tested for luciferase activity. The full length Amot 
promoter construct was activated by IL-6 as expected. In addition, a deletion of 
394 base pairs from the 5’ end of the full length promoter construct was still 
responsive to IL-6, despite a reduced basal activation. Finally, the remaining 
serial deletion constructs were no longer IL-6 responsive. The basal promoter 
activity was also nearly completely lost once 910 base pairs from the 5’ end of 
the full length was deleted (Fig 6-8B). These data indicated that the most 
relevant region of the Amot promoter with respect to responsiveness to IL-6 
treatment occurs between locales -1079 and -770 base pairs (Fig 6-8A; B). As 
discussed in Chapter 5, data obtained from ENCODE’s Chip-Sequencing catalog 
revealed the identities of the transcription factors that bind this critical region as 
NFϒA, MAZ, NFϒB, IRF1, Sp2, FOS, PBX3, ZBTB7A, and Sp1 (Fig 5-8A). The 
factors occurring in this region that have demonstrated activation in response to  
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Figure 6-8. The Amot promoter is activated by IL-6 within a 
responsive region between -770 and -1079 bps. The serial 
deletion constructs (-1079, -770, -563, -225) in addition to the full 
promoter (-1473) were each transfected into HEK 293T cells and 
treated with 0.5 ng/mL IL-6 or vehicle control for a duration of 20 
hrs and measured for luciferase activity. N=9, S.E., Student’s T-
test, *p < 0.01.  The transcription factors binding the 
predominant IL-6 responsive region between -770 and -1079 
were mapped.   
 
 
 
  
120 
IL-6 are interferon regulatory factor 1 (IRF1) and Specificity Protein 1 (Sp1) 
[87,88,93,94,173,186-188]. Likewise, ENCODE revealed that of all the factors  
binding the IL-6 responsive element, Sp1 exhibited the greatest cluster score, a 
measurement representing the signal strength detected via transcription factor 
Chip-Sequencing experiments. Finally, data from over 700 breast cancer tissue 
samples in The Cancer Genome Atlas (TCGA) showed the positive correlation 
between AMOT and SP1 transcript levels. It can be noted here that the majority 
of the >700 breast tumor tissues analyzed in the TCGA came from surgical 
excisions of DCIS tumors. This was also matched with a significant positive 
correlation with STAT3 transcript levels, a canonical transcriptional output from 
IL-6 stimulation. (Fig 6-9). Literature demonstrated that active STAT3 not only 
stimulates the nuclear translocation of Sp1, but also correlated with elevated Sp1 
transcript and protein expression [87,88,93,186]. Taken together, these pieces of 
evidence lend strong support to the hypothesis that IL-6 activates STAT3 to 
foster enhanced Sp1 transcription factor binding to the Amot promoter and 
subsequent activation of Amot expression.  
The importance of Sp1 binding to the Amot promoter was investigated via 
testing the impact of point mutations in the five SpX motif sites (GGGCGGG) 
occurring within the IL-6 responsive element on the ability of IL-6 to induce 
promoter activation. Through the detection of luciferase activity, cells transfected 
with the 5X Sp1 mutant promoter revealed a dramatic reduction in the activation 
of the Amot promoter in response to treatment with IL-6 as compared to 
treatment of cells expressing the control promoter (Fig 6-10A). The wild type   
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Figure 6-9. Amot transcript levels significantly correlate with the 
transcript levels of the Amot promoter transcription factor binders 
BACH1, MAZ, SP1, and RUNX as well as STAT3 transcript levels in 
breast cancer tumors. Analysis of >700 breast tumor tissues in The 
Cancer Genome Atlas (TCGA) sought out significant correlations (≥ +/- 0.3) 
between the transcript levels of AMOT and the transcript levels of the 
transcription factors found to bind the Amot promoter. High correlative 
transcripts are labelled in red, and the correlation between AMOT and 
STAT3 transcript levels was also highlighted. MAFK, SIN3AK20, and 
ZBTB7A are not present in TCGA and thus were unable to be analyzed. 
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  Figure 6-10. Sp1 is required for the induction of Amot promoter 
activity by IL-6. A. HEK 293T cells transfected with an Amot promoter 
luciferase construct in which all five Sp GC box binding motifs existing in 
the IL-6 responsive element were mutated and were treated with 0.5 ng/mL 
IL-6 or vehicle control for a duration of 20 hrs. Luciferase activity was 
measured and compared to the wild type Amot promoter. N=12, S.E., 
Student’s t-test, *p < 0.01. B. HEK 293T cells were transfected with the full 
length Amot promoter, treated with 0.5 ng/mL IL-6, 20 µM Mithromycin 
(MM), IL-6 and MM, or vehicle control for a duration of 20 hrs, and 
measured for luciferase activity. N=3, S.E., Student’s t-test, *p < 0.01. 
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promoter was also tested against treatment with 20 µM Mithramycin (MM) in the 
presence or absence of IL-6 (Fig 6-10B). MM is an antibiotic produced by 
Streptomyces argillaceus that inhibits transcription factor binding to GC-rich 
motifs in a competitive manner [91,189,190]. It is in this way that MM prohibits 
Sp1 DNA binding capacities and has lended itself to a wide variety of anti-cancer 
studies in every tissue type from the breast and cervix to the bones and brain 
[89-92,189-192]. Comparable to the impact of Sp GC motif point mutants on 
Amot promoter activity, treatment with MM on top of IL-6 inhibited the ability of IL-
6 to activate the Amot promoter (Fig 6-10B). As a follow up to this result, the 
impact of infection of Sp1 short hairpin RNA (shRNA) lentivirus and MM 
treatment on Amot transcript and protein levels was detected via RT-PCR and 
immunoblot. These data yielded a reduction of Amot transcript levels in both 
cases of Sp1 disruption (Fig 6-11A-B).  
Studies have shown the requirement of Sp1 in the activation of CTGF 
[193-195]. These studies focus on the fact that Sp1 binds the promoter of CTGF. 
ENCODE shows that Sp1 binds the CTGF promoter with a cluster score of 477 
out of 1000 [96]. Here, we show that the induction of CTGF transcription by IL-6 
was inhibited by the silencing and inactivation of Sp1 by shRNA in both SKBR3 
(Her2+) and MCF7 (ER+) cells (Fig 6-12A; B; 6-13B). In addition, the IL-6 
induced growth phenotype was also mitigated by the silencing of Sp1 by shRNA 
in Her2+ breast cancer cells (Fig 6-13A; C). These data are in agreement with 
that from multiple groups that have shown that Sp1 is required for the induction 
of growth by pro-inflammatic factors [74,89,90,92,195]. In parallel, the  
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Figure 6-11. Sp1 is required 
for Amot expression. A. 
MDA-MB-468s were treated 
with 20 µM MM and measured 
for TOTAL AMOT mRNA and 
protein levels. N=3, S.D., 
Student’s t-test, *p < 0.01. B. 
HEK 293T cells were infected 
with Sp1 shRNA lentivirus and 
measured for Total Amot 
mRNA and protein levels N=3, 
S.D., Student’s t-test, *p < 0.01. 
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Figure 6-12. Sp1 depletion inhibits the elevation of CTGF transcript 
levels by IL-6. SKBR3 (A) and MCF7 (B) cells infected with Sp1 shRNA or 
shScramble virus were treated with 1 ng/mL IL-6 for a duration of 24 hours 
and harvested for RNA. The levels of CTGF and STAT3 mRNA were 
detected via qRT-PCR. Silencing was confirmed by immunoblot. 
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Figure 6-13. IL-6 requires Sp1 to induce CTGF transcription and growth in 
poorly differentiated Her2+ breast cancer cells.  A-B. SKBR3 cells infected 
with Sp1 shRNA were seeded into a laminin-rich 3D Matrigel© environment, 
treated with 0.1 ng/mL IL-6 or vehicle control for a duration of 4 days, and 
measured for CTGF mRNA levels. N=3, S.D., Student’s t-test, *p < 0.01. Cells 
were confirmed for silencing via immunoblot. C. Cells from A were imaged and 
the cross sectional area of the acini was quantified with ImageJ software. N=3, 
S.E., *p < 0.01, **p < 0.001. *Note: this experiment was attempted in MDA-MB-
468 cells and yielded dramatic and rapid cell death. 
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significance of the Amot isoforms to this signaling was also demonstrated in cells 
infected with the Amot CRISPR, shRNA, or corresponding control plasmids, and 
treated with IL-6 or vehicle control. Upon the silencing of Amot, the induction of 
CTGF transcription by IL-6 was lost. This effect was seen in Amot silenced Her2+ 
and triple negative cells, where IL-6 also lacked the expansive growth phenotype 
seen in the control cells. (Fig 6-14; 6-15; 6-16). Unfortunately, our efforts to 
investigate whether IL-6 signaling favors the unphosphorylated form of the Amot 
p130 protein, and thereby enhancing its stability, remain unsuccessful. However, 
the dramatic loss of CTGF signaling upon the inhibition of the Amot TSS and a 
more than 50 % reduction in Amot transcript levels in the Amot CRISPR 1A cells 
indeed suggests the relevance of Amot promoter activity followed by elevated 
Amot transcription to this system (Fig 6-14). These data demonstrate two 
possible theories.  
Treatment of YAP1-silenced cells with IL-6 not only resulted in a mitigated 
growth phenotype, but also exhibited reduced CTGF mRNA levels when 
compared to control cells (Fig 6-16A-C). Verteporfin (VP), an inhibitor of the 
YAP1-TEAD interaction currently employed in treating macular degeneration 
[196,197], was used to test the specific requirement of the YAP1-dependent 
coactivation of TEAD on the stimulation of CTGF transcript levels in response IL-
6. Treatment with VP alone or VP in combination with IL-6 demonstrated that the 
inhibition of the coactivation of TEAD by YAP1 and subsequent lack of CTGF 
transcript elevation may be sufficient to mitigate the IL-6 growth phenotype (Fig  
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elevation of CTGF by IL-6.  A. HEK 293T cells infected with Amot 
CRISPR 1 were puromycin selected and clones were picked (CRISPR 
clone 1A or CRISPR clone 1B) or allowed to establish a bulk population. 
Cells were harvested for protein and probed for Amot and GAPDH 
loading control. B. CRISPR clone 1A and control cells from (A) treated 
with 1 ng/mL IL-6 for a duration of 24 hours were harvested for RNA and 
of CTGF and Amot mRNA levels were detected via qRT-PCR. 
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Figure 6-15. IL-6 requires Amot to induce CTGF transcription and 
growth in poorly differentiated Her2+ breast cancer cells.  A-B. SKBR3 
cells infected with Amot shRNA were seeded into a laminin-rich 3D Matrigel© 
environment, treated with 0.1 ng/mL IL-6 or vehicle control for a duration of 4 
days, and measured for CTGF mRNA levels. N=3, S.D., Student’s t-test, *p < 
0.01. Cells were confirmed for silencing via immunoblot. C. Cells from A were 
imaged and the cross sectional area of the acini was quantified with ImageJ 
software. N=3, S.E., *p < 0.01, **p < 0.001. 
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Figure 6-16. IL-6 requires Amot to induce CTGF transcription and growth in 
moderately differentiated triple negative breast cancer cells.  A-B. MDA-MB-468 
cells infected with Amot shRNA were seeded into a laminin-rich 3D Matrigel 
environment, treated with 0.1 ng/mL IL-6 or vehicle control for a duration of 4 days, 
and measured for CTGF mRNA levels. N=3, S.D., Student’s TTest, *p < 0.01. Cells 
were confirmed for silencing via immunoblot (B). C. Cells from A were imaged and the 
cross sectional area of the acini was quantified with ImageJ software. N=3, S.E., *p < 
0.01, **p < 0.001. 
 
A 
B 
C 
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in moderately differentiated triple negative breast cancer cells. A-B. MDA-
MB-468 cells infected with Amot shRNA were seeded into a lamini-rich 3D 
Matrigel environment, treated with 0.1 ng/mL IL-6 or vehicle control for a 
duration of 4 days, a d meas red for CTGF mRN l vels. N=3, S.D., 
Student’s TTest, *p< 0.01. Cells were confirmed for silencing via immunoblot 
(B). C. Cells from A were imaged and the cross sectional area of the acini was 
quantified with ImageJ software. N=3, S.E., *p<0.01, **p<0.001. 
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Figure 6-17. IL-6 requires YAP1 to induce CTGF transcription and growth in 
moderately differentiated ER + breast cancer cells.  A-B. MCF7 cells infected 
with YAP11 shRNA were seeded into a laminin-rich 3D Matrigel environment, 
treated with 0.1 ng/mL IL-6 or vehicle control for a duration of 4 days, and 
measured for CTGF mRNA levels. N=3, S.D., Student’s t-test, *p < 0.01. Cells 
were confirmed for silencing via immunoblot (B). C. Cells from A were imaged and 
the cross sectional area of the acini was quantified with ImageJ software. N=3, 
S.E., *p < 0.01, **p < 0.001. *Note: this experiment was attempted in MDA-MB-
468 cells and SKBR3s and yielded dramatic and rapid cell death. 
 
 
A 
B 
C 
  
132 
  
*
0.0
1.0
2.0
3.0
N=3
VP IL-6 IL-6 +
VP
Vehicle
*
R
e
la
tiv
e
 L
e
ve
ls
 o
f
C
T
G
F
 m
R
N
A
(D
D
C
T
)
VPVehicle VP + IL-6IL-6
9
6
 H
o
u
rs
2
4
 H
o
u
rs
0.0
1.0
2.0
3.0
4.0
5.0
IL-6
VP
+ + + +- - - -
+ +- -- - + +
Day 1
Day 4
R
e
la
ti
v
e
A
c
in
i 
S
iz
e
N=3
* * N.S.
Figure 6-18. IL-6 requires the coactivation of TEAD by YAP1 to induce 
CTGF transcription and growth in moderately differentiated ER + breast 
cancer cells.  A-B. MCF7 cells were seeded into a laminin-rich 3D Matrigel© 
environment, treated with treated with 0.1 ng/mL IL-6, 1µM Verteporfin (VP), IL-
6 and VP, or vehicle control for a duration of 4 days, and measured for CTGF 
mRNA levels. N=3, S.D., Student’s t-test, *p < 0.01. C. Cells from A were 
imaged and the cross sectional area of the acini was quantified with ImageJ 
software. N=3, S.E., *p < 0.01, **p < 0.001. *Note: this experiment was 
attempted in MDA-MB-468 cells and SKBR3s and yielded dramatic and rapid 
cell death.  
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6-17A-C). The direct induction of CTGF transcription by the co-activation of the 
TEAD transcription factor by YAP1 to stimulate the CTGF promoter is widely 
published [103-106,117,119,139,198-201]. ENCODE shows that TEAD binding 
of the CTGF promoter produced a strong signal with a cluster score of 1000 [96]. 
In addition to the validated binding of Sp1 and TEAD4 to the CTGF 
promoter, ENCODE also shows that STAT3 binds the CTGF promoter with 
cluster score of 137 [96]. The observation of the correlated binding of TEAD, 
Sp1, and STAT3 on the CTGF promoter, in combination with the convergence of 
YAP1-TEAD, STAT3, and Sp1 signaling in the promotion of cell growth, led us to 
wonder if other genes were regulated by the simultaneous binding of these three 
transcription factors. To determine the identities of these genes, we first cross 
referenced YAP1 occupied gene promoters with TEAD occupied gene promoters 
found in chromatin immunoprecipitation assays by Zhao et al. 2008 in order to 
select for the YAP1-TEAD complex activated genes [202]. Subsequently we 
configured the transcription factor binding site (TFBS) track in ENCODE to 
isolate the binding of TEAD4, Sp1, and STAT3. We then searched the genes of 
all 1,968 YAP1-TEAD occupied promoters. We recorded whether Sp1 and/or 
STAT3 binding occurred within 3 kilobases upstream of the TSS of each gene. A 
total of 451 genes were not found in the UCSC genome browser, so these genes 
were thrown out. Our analysis resulted in the creation of four distinct gene lists: 
1) 531 gene promoters bound by the YAP1-TEAD complex, 2) 471 gene 
promoters bound by both Sp1 and YAP1-TEAD, 3) 117 gene promoters bound 
by STAT3 YAP1-TEAD, and 4) 398 gene promoters bound by STAT3, Sp1, and 
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YAP1-TEAD. We then set out to compare the oncogenic impact of the four 
different gene lists. For this task we employed the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) functional annotation software, a 
database that clusters genes based on various parameters including cellular 
function, correlation to diseases, protein domains, subcellular localizations, and 
many others. The OFFICIAL_GENE_SYMBOL of the genes in all four gene lists 
were uploaded separately and analyzed for KEGG Pathway(s) and gene-disease 
associations. Interestingly, the DAVID analysis found that only the genes 
simultaneously bound by YAP1-TEAD, Sp1, and STAT3 correlated with cancer-
associated diseases (Fig 6-19). No other parameters available in DAVID showed 
notable differences between the four gene lists [203]. This novel finding further 
establishes the importance of the converged signaling between HIPPO pathway 
dysregulation and the pro-inflammatory secretion of IL-6 to drive nuclear STAT3 
and Sp1.      
6.4 Discussion 
As discussed in Chapter 4, high Amot expression in breast cancer has 
been shown to correlate with a poor prognosis and a marked reduction in patient 
survival [132]. A vast amount of work completed by the Wells group and others 
has demonstrated the significance of the Angiomotins with regard to directing 
intracellular YAP1 localization in a context-dependent manner. It is regarded that 
this correlation of Amot to poor prognosis is due to its function as a prominent 
driver of YAP1 nuclear translocation to foster a pro-growth and pro–survival 
phenotype through the activation of YAP1 target genes such as CTGF. The link  
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  Figure 6-19. Genes that are simultaneously bound by YAP1-TEAD, Sp1, 
and STAT3 correlate with cancer associated genes, in contrast to genes 
that are bound by only YAP1-TEAD, by Sp1 and YAP1-TEAD, or by 
STAT3 and YAP1-TEAD.  Genes of YAP1-TEAD occupied promoters were 
observed for Sp1 and/or STAT3 binding using the Encyclopedia of DNA 
Elements (ENCODE) in the UCSC genome browser. The resulting gene lists 
were analyzed using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) software for the clustering against the 
parameter of cancer-associated diseases.  
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between IL-6 and/or STAT3 signaling to YAP1 pro-growth signaling only first 
appeared in the literature in 2014; four studies have demonstrated this 
connection in breast, liver, intestine, and adipocytes [121,177,182,204]. An 
impressive 91 studies dating back to 2001 have shown a connection between IL-
6 and CTGF. However, very little has been done to elucidate the mechanism by 
which IL-6 activates YAP1 and/or elevates CTGF transcripts. In preliminary 
experiments, there was indeed a time-dependent influence of IL-6 on Amot 
protein levels (Fig 6-5C) but not on YAP1 protein levels; This proposed a 
potential for Amot-dependent YAP1 nuclear trans-localization to be critically 
important in the signaling between IL-6 and CTGF.   
The fact that the elevation of Amot promoter activity in response to IL-6 is 
returned to basal levels by STAT3 inhibition (Fig 6-7), yet the reduction of basal 
STAT3 levels by shRNA yielded Amot protein levels that were markedly reduced 
in comparison to control highlight the potential for enhanced protein degradation 
in addition to reduced transcriptional activation of Amot upon reduced basal 
STAT3 levels (Fig 6-6A). All of these data, despite the fact that no STAT3 binding 
occurs in the Amot promoter, indicate that IL-6/STAT3 activate the Amot 
promoter through another IL-6 responsive transcripton factor.  
Both STAT3 and Sp1 have demonstrated abilities to independently 
activate over 3000 promoters in the cell [87]. Additionally, it is widely known that 
activated STAT3 can function to recruit Sp1 to the nucleus to enhance Sp1 DNA 
binding activity and activation of growth and survival genes [93]. The literature 
supports the ability of Sp1 to directly bind and strongly activate CTGF, 
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independent of Amot [74]. However, our data show that this signaling, with 
regard to CTGF promoter activity, is mitigated in conditions where Amot or YAP1 
are silenced, or YAP1 is inhibited (Fig 6-15-6-18). This demonstrates that the 
activation of the CTGF promoter by IL-6 exploits the activation of YAP1 by Amot. 
Sp1 binding of the Amot promoter is therefore required in order for IL-6 to induce 
cell growth (Fig 6-18).  
Altogether, this work has provided novel insights into the location of the 
start of transcription of the AMOT gene, a primary mechanism of transcriptional 
control of the Amot isoforms, and the necessity of the Amot isoforms to direct 
growth and signaling in response to IL-6. 
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CHAPTER 7: DISCUSSION 
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For this dissertation, we sought to address whether the dysregulation of 
HIPPO signaling, through the increased expression of the Angiomotin isoforms, 
plays a role in DCIS to IDC transitions in mammary tissue. To answer this broad 
question, we focused our efforts in addressing a number of specific points 
expanded upon below. 
 
7.1 Total Amot expression levels are greater and its subcellular localization is 
altered in more aggressive forms of breast cancers.  
The first point we addressed was to associate the histologic measures of 
Amot protein expression and subcellular localizations with reports of enhanced 
levels of Amot transcripts in breast tumors. Our data recapitulated the following 
results from Jiang et al. 2006 and Lv et al. 2015: We found that Amot protein 
expression is indeed elevated in breast cancers (Fig 4-2A), that it exhibits a 3-
fold increase in pre-metastatic tumor samples than in those that did not 
metastasize (Fig 4-7), and that Amot levels show no direct correlation to estrogen 
or progesterone receptor statuses (Fig 4-3, 4-4) [132, 133].  
Additionally, our work disagreed with Jiang et al. 2006 which reported that 
Amot mRNA levels are increased in tumors from patients diagnosed with the 
more aggressive node positive breast cancer disease, yet showed no marked 
increase in Amot mRNA in pre-recurrent tumor samples [132]. Our results, 
however, revealed no significant difference between samples from node positive 
verses node negative diagnoses (Fig 4-6), but surprisingly yielded a more than 3-
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fold increase in Amot protein expression in pre-recurrent tumor samples over 
non-recurrent samples (Fig 4-8). The combination of the following findings 
strongly indicate the significance of Amot expression in highly aggressive forms 
of breast cancer: the rise of Amot mRNA in the more aggressive node-positive 
tumors [132], the proliferating cancer cells within the tumor exhibited the highest 
degree of Amot staining [133], elevated Amot mRNA correlated with a high 
hazard ratio [Bringman unpublished], and the correlation of increased Amot 
expression in pre-metastatic (Fig 4-7) [132] and pre-recurrent breast tumor 
samples (Fig 4-8).  
Furthermore, our study extended beyond the current literature and 
provided insights into the incidence and roles of elevated Amot expression in 
those tumor samples undergoing the transition from DCIS to IDC. We found that 
Amot protein expression is over 4-fold higher in transitioning tumors, 
characterized as IDC with a predominant presence of DCIS, than in those tumors 
where IDC seemingly developed de novo (Fig 4-9). Our analysis of the staining 
pattern of Amot in the majority of these samples exhibited Amot occurring in juxta 
nuclear punctae (Fig 4-10). The staining of Amot in this pattern has strongly 
correlated with the high association of Amot 80 with proteins to drive a pro-
migratory phenotype [166]. Additional work from the Wells lab has demonstrated 
that YAP1 co-localizes with the Amots exhibiting this same punctal pattern in 
fixed cell imaging of cells co-expressing Amot 130 and Amot 80 (data not 
shown). It is also important to note that as Amot 80 does not possess the motif 
required to bind YAP1 (Fig 1-10), Amot 130 is indeed necessary to this co-
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localization of YAP1 to these juxta nuclear punctae, and therefore is evidence to 
support that this is a complex formation resulting from the dimerization of Amot 
130 and Amot 80. This juxta nuclear Amot staining was also observed in cells 
within the tissue that appear to be in the process of invading the stroma.  
In summation, this particular work adds significant information to the field 
of HIPPO signaling with respect to Amot expression in human breast cancer 
tissues. Not only are we the first to distinguish Amot as a potential marker of 
DCIS to IDC transitional events, but we are also the first to show explicit, highly 
specific Amot fluorescent staining in human breast tumor tissue samples. This 
accomplishment has allowed us to associate the levels of Amot with cells at 
different phases of differentiation by relating Amot localization to nuclear, diffuse, 
and junctional staining.  
We would like to complete follow up studies that compare additional 
invasive breast tumor samples with and without predominant DCIS lesions using 
immunofluorescent imaging. The ability to perform immunoblot analyses on these 
tissues would also provide a quantifiable measure of the protein expression 
levels of the individual Amot isoforms. Furthermore, the imaging of additional 
samples could also aid in establishing stronger correlations between the various 
Amot staining patterns and clinical features of breast tumors, such as HER2 
status, and patient follow up data, such as survivorship. Comprehensively, this 
work could result in the Amot isoforms becoming a prognostic marker of DCIS 
lesions at risk for transitioning to IDC and potentially prevent unnecessary 
surgeries for those DCIS patients that exhibit low Amot expression. 
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7.2 The mRNA expression of the Amot isoforms is controlled by a single 
promoter and result from alternative pre-mRNA splicing. 
The potential role of Amot proteins in DCIS to IDC transitions motivated us 
to question how their expression is controlled. The literature is currently lacking 
of any thorough investigation into this, but rather focuses on the altered activity of 
Amot 130 due to mechanisms of post-translational modifications [117,128, 
137,138]. Preliminary data, including TCGA analysis of over 700 breast tumor 
samples, supports the significance of Amot mRNA expression in aggressive 
breast cancers (Bringman unpublished). Moving forward, we concentrated 
heavily on molecular biology techniques in order to address our second point of 
this thesis work, which was to define the AMOT gene, its regulatory region(s), the 
promoter element(s) that control its transcription, and the manner in which the 
unique isoforms are expressed. Our work is the first to identify a single 
transcription start site controlling the mRNA expression of both Amot 130 and 
Amot 80 isoforms. This new information provided us with the following insights: 1. 
Both the Amot 130 and 80 isoforms are regulated by a single promoter upstream 
of GChr37: 112840790 2. These isoforms are results of alternative pre-mRNA 
splicing (Fig 5-2-5-5). 
Regarding insight 1, the definition of a sole TSS not only highlights the 
specific set of transcription factors that are likely responsible for regulating Amot 
isoform transcription, it also dispels the likelihood that the active chromatin region 
upstream of exon 2 could be an additional regulatory element for the transcription 
of both or either isoform. With no H3K4me3 marks, this region of loosened 
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histones more likely serves as intron/exon boundary [206] (Fig 5-1). This result 
served as the basis for the design and study of the Amot promoter reporter 
construct; a reagent that possesses interminable potential for studying the 
regulation of Amot transcription. Furthermore, we verified the region of the Amot 
promoter that is key to driving Amot transcription, therefore narrowing down a 
subset of transcription factors that are significant to this system (Fig 5-8). As the 
Amot isoforms serve as the predominant director of YAP and TAZ subcellular 
localizations, the study of the transcription factors that modulate their expression 
is central to the understanding of HIPPO signaling.  
With respect to insight 2, we identified the data that supports a notion that 
the field has been assuming for over a decade: the Amot isoforms are indeed 
splice variants of each other. Ascertaining the 5’ leader exons unique to each 
isoform has provided our lab with the first ever primer sets to distinguish these 
gene products (Fig 5-7). These reagents hold the power both to aid in the 
identification of potential factors that drive the alternative splicing of the Amot 
isoforms as well as serve as the detection method to establish these isoforms as 
possible biomarkers for DCIS to IDC transitions. 
To conclude, these data not only provide the field with a greater 
understanding of the AMOT gene architecture, but also yielded a set of biological 
tools for the detection and study of the transcriptional regulation of a key set of 
proteins that govern the activity of the YAP and TAZ oncogenes. These tools will 
allow for the future studies investigating which transcription factors are required 
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to modulate Amot transcription as well as which factors drive Amot 80 verses 
Amot 130 favored mRNA splicing.   
 
7.3 The enhanced expression of pro-tumorigenic genes by IL-6 is Amot-
dependent and requires coordinated Sp1, STAT3, and YAP1-TEAD promoter 
occupancy.  
 The concentrations of pro-inflammatory cytokines present in the mammary 
stroma and sera are greatly increased in patients that experienced a transition of 
DCIS to IDC [10,35,38]. To accompany our finding that Amot levels are higher in 
IDC tissues with predominant presence of DCIS lesions, we sought to define the 
impact of inflammatory cytokine induced signaling on Amot expression. To 
address this, we tested Amot promoter activity against three key cytokines in the 
promotion of breast cancer: IFNγ, TNFα, and IL-6. Treatment with IL-6 produced 
the greatest impact on Amot promoter activity (Fig 6-1A, 6-7, 6-8B); this is also in 
agreement with our mRNA and immunoblot analysis showing a dramatic 
induction of both Amot 130 and Amot 80 transcript and protein expression (Fig 6-
2, 6-5, 6-6).  
Regarding the question of how inflammation innervates dysregulated 
HIPPO signaling, we sought to establish the importance of Amot as an effector of 
inflammatory induced cell dedifferentiation and proliferation. Our data revealed 
that the stimulation of Amot depleted cells with IL-6 not only displayed a 
mitigated tumor phenotype, but also a markedly reduced cell growth and CTGF 
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transcriptional activation (Fig 6-14-6-16). We also observed a dramatic loss of 
both Amot and protein levels following the silencing of STAT3 (Fig 6-6), an event 
so widely demonstrated to radically impede tumor growth that it has fostered the 
generation of a plethora of STAT3 inhibitor drugs. The depletion of YAP1 protein 
levels was also observed in response to STAT3 silencing (Fig 6-6C), warranting 
our further investigation into the requirement of YAP protein for the IL-6 induced 
growth phenotype and CTGF transcriptional activation. This led to our novel 
discoveries that both YAP1 protein expression and its co-activation of TEAD are 
necessary and sufficient events in tumorigenic progression by IL-6 (Fig 6-17, 6-
18). Additionally, because the CTGF promoter is directly bound and activated by 
the YAP-TEAD complex [110-128; 204], the loss of tumorigenic growth exhibited 
in Verteporfin-treated cells, despite stimulation by IL-6, only further raises the 
significance of CTGF to the efficiency of IL-6 to promote tumorigenesis in these 
cells.    
 Finally, our pursuit of the identification of the key factors in inflammatory 
based signaling that induce Amot transcription revealed that Sp1, a well-studied 
cooperative effector of IL-6 signaling [87,93,94] is not only required for 
enhancement of Amot expression by IL-6, but also the IL-6 induced activation of 
CTGF transcription. The impact of Sp1 on the activation of CTGF has been well-
established in response to TGFβ signaling [98], but never examined in response 
to stimulation by IL-6. Sp1 has, however, been implicated in the coordinate gene 
transcription with its sometimes binding partner PSTAT3, an event commonly 
stimulated by IL-6 signaling [93-94]. The fact that the Amot promoter does exhibit 
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Sp1 but not STAT3 binding (Fig 6-8A), and its activation in response to IL-6 is 
both STAT3 and Sp1 dependent (Fig 6-7, 6-8B, 6-10), raises the likelihood that 
the AMOT gene, like many others studied in the literature, is regulated by this 
concordant mechanism of IL-6 induced Sp1 and STAT3 cooperative promoter 
co-occupancy [93, 94]. Interestingly, ENCODE analysis revealed that the CTGF 
promoter is in fact bound by STAT3, Sp1, and TEAD4. Since CTGF mRNA levels 
are so tightly coupled to dysregulated HIPPO signaling that the transcript in fact 
serves as a chief control readout for nuclear YAP1 activity [110-128; 204], we 
decided to explore the frequency that STAT3 and Sp1 co-transcription factors co-
occupy other gene promoters with validated YAP1-TEAD binding [204]. This 
effort resulted in the first comprehensive bioinformatic study of Sp1, STAT3, and 
YAP1-TEAD promoter co-occupancy. Surprisingly, ENCODE and DAVID 
analysis revealed that all of the pro-tumorigenic genes that are co-activated by 
YAP1-TEAD also exhibited binding by both STAT3 and Sp1. Conversely, the 
DAVID analysis revealed that no cancer-associated genes occurred within the 3 
lists of gene promoter occupancy of 1) YAP1-TEAD alone, 2) Sp1 and YAP1-
TEAD co-occupancy, and 3) STAT3 and YAP1-TEAD co-occupancy. Because 
the Amot isoforms serve as the predominant directors of YAP1-TEAD activity 
[117], and we have confirmed that the IL-6 induced pro-growth phenotype in 
breast cancer is both dependent upon the presence of Amot and the nuclear 
complex formation of YAP1-TEAD (Fig 6-14-6-18), this data only further supports 
the significance of this discovery that the innervation of pro-inflammatic IL-6 with 
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the down-regulation of HIPPO signaling to tumorigenic growth in breast cancer 
cells. 
This collection of data is the first to define a mechanism by which pro-
inflammatic IL-6 signaling in the microenvironment of breast cancer cells can 
drive the loss of intracellular polarity regulation by HIPPO signaling via enhanced 
Amot expression (Fig 6-5, 6-6). This, in turn, drives the YAP-nuclear 
translocation which fosters the pro-tumorigenic growth akin to the IL-6 signaling 
effect in the pro-inflammatic tumor microenvironment in a variety of cancers, 
including those arising from the mammary gland (Fig 6-3A, 6-17, 6-18) [81,82, 
84-87]. As the literature has observed that levels of IL-6 are increased in 
transitioning IDC tumors [10, 35, 38], these findings support the likelihood that IL-
6 and Amot levels are coordinately increased in IDC tumors with predominant 
DCIS lesions over de novo IDC. 
Although the impacts of IL-6 signaling on TAZ levels and activity was only 
briefly touched upon, the fact that we saw the silencing and inactivation of YAP1 
alone was sufficient to impede the IL-6 induced growth phenotype and CTGF 
transcription demonstrated either that: 1. TAZ alone is incapable of overcoming 
the loss of YAP activity, or 2. That the effect we see on YAP1 is actually mimetic 
of the effects on TAZ. Regardless of the answer, this sufficiently dispels the urge 
to study this particular interconnected signaling mechanism with respect to 
HIPPO transcriptional coactivator TAZ [107, 108]. However, the results from this 
work do highlight the potential for additional studies that investigate whether the 
activity and stability of the Amot proteins is impacted in response to IL-6. Our 
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preliminary analysis of whether treatment with IL-6 increases the stability of the 
Amot isoforms was inconclusive, but it certainly continues to be worthy of 
pursuing, particularly in the case of Amot 130 and its ability to be phosphorylated 
and targeted for degradation [137, 138]. In addition, our data showed that the 
transcriptional activation of the Amot isoforms through this mechanism did not 
exhibit alternative splicing (Fig 6-4), but our identification of the active region in 
the Amot promoter identifies a variety of transcription factors that could be 
impacted by signaling from other cytokines commonly present in a pro-
inflammatic tumor microenvironment Fig 6-8).  Moreover, the opportunity to 
correlate Amot expression and staining patterns within tumor tissue samples 
exhibiting either greater phosphorylated STAT3 levels or an increased presence 
of activated lymphocytes and/or macrophages would provide further validation 
that this signaling mechanism is translationally relevant (Fig 1-2).  
 Additionally, this work raises a variety of questions regarding the role of 
the Amot isoforms in response to wound healing as well as in the mechanism of 
de-differentiation during and EMT event. While a number of studies discuss the 
possible connection of the Amots to these cellular processes, the research 
investigating these connections is still greatly deficient. The work we have done 
to establish the convergence of pro-inflammatic IL-6 signaling, a pathway heavily 
implicated in both the facilitation of wound healing and the driving of EMT events 
[70, 72, 75-77], with the dysregulation of HIPPO polarity signaling has created a 
solid foundation for its applications in wound healing and EMT studies.       
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APPENDIX – NUCLEOTIDE SEQUENCES 
 
5’ RACE PRIMERS 
5’ Linker Primer: 5’-
GCTGATGGCGATGAATGAACACTGCGTTTGCTGGCTTTGATGAAA-3’ 
3’ Amot Exon 2 Primer: 5’-
AGCTAGCTGTTAATTAATCAGGCTTCGGTCCCGGGCC-3’ 
3’ Amot Exon 4 Primer: 5’- 
 
qRT-PCR PRIMERS  
 
CTGF Forward: 5’-AGGAGTGGGTGTGTGACGA-3’ 
CTGF Reverse: 5’-CCAGGCAGTTGGCTCTAATC-3’ 
 
AMOT 130 Forward: 5’-AGAGGCACCACCAGCAATAGAGAAGC 
AMOT 130 Reverse: 5’-GGGCGTCCCTCAGTCCTCATGC 
 
AMOT 80 Forward: 5’-TAGCCGCTCACCGCAAGAAGC 
AMOT 80 Reverse: 5’-TCTGCTCGCTCAAGTGGCTTGC 
 
TOTAL AMOT Forward: 5’-GCATTCTCCTGGGTGGAGAC 
TOTAL AMOT Reverse: 5’-GATTCCGTCCCACGTTCAGT 
 
STAT3 Forward: 5’-ACCTGCAGCAATACCATTGAC 
STAT3 Reverse: 5’-AAGGTGAGGGACTCAAACTGC 
 
GAPDH Forward: 5’-CCAGGCAGTTGGCTCTAATC 
GAPDH Reverse: 5’-CCAGGCAGTTGGCTCTAATC 
 
18S rRNA Forward: 5’-CCGATAACGAACGAGACTCTGG 
18S rRNA Reverse: 5’-TAGGGTAGGCACACGCTGAGCC 
 
Pax7 Forward: 5’-AGCATCCTTAGCAACCCGAG 
Pax7 Reverse: 5’-CTCCTGGCTTGATGGAGTCG 
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shRNA CONSTRUCTS 
 
Amot shRNA:  GAGGAGAATGTGATGAGACAT  in pLKO.1 (Sigma Aldrich)  
Stat3 shRNA: Addgene-Plasmid #26596 
Sp1 shRNA: 
CCGGGCTGGTGGTGATGGAATACATCTCGAGATGTATTCCATCACCACCAG
CTTTTT in pLKO.1 (Sigma Aldrich) 
 
shScramble: Addgene-Plasmid #1864 
 
OVEREXPRESSION CONSTRUCTS 
 
CA-Stat3: Addgene – Plasmid #8722 
 
Stat3 WT: Addgene - Plasmid #8707 
 
Stat3 Y705F: Addgene - Plasmid #8709 
 
Sp1: Obtained by Dr. Mircea Ivan (IUSM) from the following manuscript:  
Dong, Z. and J. T. Zhang (2003). "EIF3 p170, a mediator of mimosine effect 
on protein synthesis and cell cycle progression." Mol Biol Cell 14(9): 
3942-3951. 
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